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1. ADENOSINE 
 
Adenosine is an ubiquitous purine nucleoside, playing a fundamental role 
in many biological processes such as energy generation and proteins metabolism, 
but in the last two decades it has become clear that adenosine is a mediator 
involved in the  pathogenesis of many inflammatory disorders. 
 
1.1. Adenosine endogenous production and metabolic pathway 
Adenosine consists of the purine base adenine in glycosidic linkage with 
ribose (Figure 1); endogenous adenosine derives from dephosphorylation of the 
nucleotide adenosine 5’-monophosphate (AMP) to adenosine by the enzyme ecto-
5'-nucleotidase, that is present in the cell membrane and belongs to the 
ectonucleotidases family; the  ectonucleotidases include ectonucleoside 
triphosphate diphosphohydrolases, ectonucleotide pyrophosphatase 
/phosphodiesterases, alkaline phosphatases and 5'-nucleotidases (Zimmermann et 
al., 2002). Under normal conditions most adenosine is derived from intracellular 
AMP that is at low levels in the cell and any AMP that accumulates, diffuses 
down its concentration gradient out of the cell and encounters the cell membrane 
ecto-5'-nucleotidase; intracellular AMP is derived from the cleavage of adenosine 
5’-diphosphate (ADP)  and adenosine 5’-triphosphate (ATP) during the cycle of 
energy generation and the dephosphorylation of AMP to adenosine is considered 
the last step of the enzymatic chain (Fredholm et al., 2001a), in fact this metabolic 
pathway lasts few hundred milliseconds and the dephosphorylation of AMP to 
adenosine seems to be the rate-limiting step (Dunwiddie  et  al., 1997). Adenosine 
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can also be formed in the intracellular environment due to the activity of 
intracellular 5'-nucleotidases of which two isoforms,  cN-I  and  cN-II,  have  been  
cloned  (Fredholm  et  al., 2001a). 
During conditions of high-energy demand, 5’-nucleotidases metabolise 
intracellular AMP to adenosine to release energy (Polosa et al., 2002); at this 
stage, the requirement for more energy leads to the breakdown of adenosine to 
inosine and hypoxanthine by the enzyme adenosine deaminase (ADA) (Trams and 
Lauter, 1974). The enzyme adenosine kinase is responsible for converting 
adenosine to AMP (which in turn is reconverted to ADP and ATP, as a part of the 
energy cycle) and is largely responsible for the resulting low levels of intracellular 
adenosine (Polosa et al., 2002). Once formed, extracellular adenosine is 
transported inside the cell by nucleoside transporters which are able to maintain 
high level of   adenosine against a concentration gradient (Fredholm et al., 2001a), 
and an increase in extracellular active levels of adenosine can be induced by drugs 
decreasing the activity of these transporters; adenosine transporters have been 
cloned and named as ENT1 and ENT2 (equilibrative transport) and CNT1 and 
CNT2 (concentrative transport).  
Under conditions of high energy demand and/or hypoxia, intracellular 
AMP is  metabolised to adenosine (Bodansky and Schwartz, 1968; Mentzer et al., 
1975); an  example  of  this  high  energy  demand  is  an  inflammatory 
environment where a large number of inflammatory cells compete for a limited 
oxygen supply. Ischemia, hypoxia and electrical stimulation can also increase the 
level of adenosine (Zetterstrom et al., 1982; Berne and Rubio, 1974) and the 
increase can be up to 100-fold  during  ischemia  (Rudolphi  et  al.,  1992); 
 9 
adenosine release is also affected by  neurotransmitters such as NMDA, dopamine 
and nitric oxide (Fredholm et al., 2001a). 
 
 
Figure 1: Adenosine structure  
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Figure 2: Adenosine metabolic pathway. Once into extracellular space, adenosine is able to 
activate adenosine receptors;  for abbreviations, see the text. 
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1.2. Biological effects of adenosine 
Adenosine is released into the extracellular fluid under physiological and 
pathological conditions (during hypoxia and ischaemia) and exerts a wide variety 
of effects on many different tissues and organ systems (Ramkumar et al., 1988; 
Feoktistov and Biaggioni, 1997; Pelleg and Porter, 1990), almost including: the 
heart (Belardinelli et al., 1989), with an antiarrhythmic/arrhythmogenic effect by 
the depression of pacemaker activities, by slowing A.V. conduction, modulating 
autonomic control and triggering synthesis and release of prostaglandins, although 
the antiarrhythmic effect is preponderant; the  kidney (Churchill et al., 1982), 
where adenosine decreases/increases renal blood flow, decreases glomerular 
filtration rate, decreases/increases renin release, stimulates renal sympathetic 
nerves; blood and blood vessels, with coronary vasodilatation and reduction of 
peripheral vascular resistance; lungs (Spicuzza et al., 2006), with 
bronchoconstriction and increment of vascular resistance; nervous system 
(Fredholm et al., 1988), where adenosine depresses neurotransmission, reduces 
neuronal firing, induces spinal analgesia, and has pro- and anti-nociceptive 
properties, neuro-protective, anti-convulsive, anti-psychotic, anxiolytic effects and 
is a locomotor activity depressant; immune system (Huang et al., 1997), generally 
inhibiting function, for example inhibiting neutrophil and platelet function, 
although adenosine has both pro- and anti-inflammatory effects. These and other 
effects are summarised in Table 1. 
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Table 1: Biological effects of adenosine (from Livingston et al., 2004; adapted from Pelleg et 
al., 1990). 
Organ Effects 
Heart Depression of pacemaker activities, slows AV conduction, 
antiarrhythmic/arrhythmogenic effect, modulatesautonomic 
control, triggers synthesis and release of prostaglandins. 
Kidney Decreases/increases renal blood flow, decreases glomerular 
filtration rate, decreases/increases rennin release, stimulates 
renal sympathetic nerves. 
Blood and 
Blood vessels 
Coronary vasodilatation, reduces peripheral vascular resistance. 
  
Lungs Bronchoconstriction, increases vascular resistance. 
Liver Vasoconstriction, stimulates glycogenolysis. 
Pancreas Potentiates glycogen release. 
Adrenals Stimulates stereogenesis. 
Central 
nervous system 
Depresses neurotransmission, reduces neuronal firing, induces 
spinal analgesia, pro-and anti-nociceptive properties, neuro-
protective effects, anti-convulsive effects, anti-psychotic effects, 
anxiolytic agent, locomotor depressant. 
Immune 
function 
Generally inhibits function e. g. inhibits neutrophil and platelet 
function, although has both pro- and anti-inflammatory effects. 
Metabolism Inhibits adipocyte lipolysis, stimulates adipocyte glucose 
oxidation, stimulates glucose uptake in the heart, regulation of 
intestinal tone and secretion. 
Other Induces breathing, induces hypothermia, sedative, activates 
cellular antioxidant enzymes, anti-diabetic, role in apoptosis, 
role in cell growth e.g. inhibits smooth muscle cell growth, 
modulates gene expression. 
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1.3. Adenosine receptors classification 
Membrane-bound receptors mediate adenosine cell signalling and 
determine the variety of its effects; at present, there are four established adenosine 
receptors in humans that have been cloned, designed as A1, A2A, A2B and A3 
receptors. These receptors are seven transmembrane-spanning proteins and 
members of the G protein-coupled receptors; they belong to the large family of 
the so-called purinergic receptors, which are subdivided in P1 (activated by 
adenosine) and P2 (activated by ATP). Adenosine and its agonists act via these 
receptors and are able to modulate the activity of adenylate cyclase, the enzyme 
responsible for increasing cyclic AMP (cAMP); the different receptor subtypes 
have differential stimulatory and inhibitory effects on this enzyme and bind 
extracellular adenosine with different affinities, as reported in Table 2 (Ralevic & 
Burnstock, 1998; Fredholm et al., 2001a; Bours M.J.L. et al., 2006). It must be 
noted that adenosine breakdown product inosine also exhibits agonistic action on 
A1, A2A, A2B and A3 receptors at micromolar concentrations (Jin et al., 1997; 
Fredholm et al., 2001b; Gomez & Sitkovsky, 2003; Hasko et al., 2004). 
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Table 2: P1 and P2 receptor subtypes with estimated affinity for physiologic ligands (from 
Bours M.J.L. et al., 2006). 
Subtype Physiologic ligand 
 
P1 receptors 
A1 Adenosine (EC50: 0.18–0.53 µM) 
Inosine (EC50: 290 µM) 
A2A Adenosine (EC50: 0.56–0.95 µM) 
Inosine (EC50: 50 µM) 
A2B Adenosine (EC50: 16.2–64.1 µM) 
A3 Adenosine (EC50: 0.18–0.53 µM) 
Inosine (EC50: 0.03–2.5 µM) 
 
P2 receptors 
P2X1 ATP (EC50: 0.05–1 µM) 
P2X2 ATP (EC50: 1–30 µM) 
P2X3 ATP (EC50: 0.3–1 µM) 
P2X4 ATP (EC50: 1–10 µM) 
P2X5 ATP (EC50: 1–10 µM) 
P2X6 ATP (EC50: 1–12 µM) 
P2X7 ATP (EC50: 100–780 µM) 
 
P2Y1 ADP (EC50: 8 µM) 
P2Y2 UTP (EC50: 0.14 µM) = ATP (EC50: 0.23 µM) 
P2Y4 UTP (EC50: 2.5–2.6 µM) » ATP, UDP 
P2Y6 UDP (EC50: 0.3 µM) »UTP (EC50: 6 µM) 
P2Y11 ATP (EC50: 17 µM) 
P2Y12 ADP (EC50: 0.07 µM) 
P2Y13 ADP (EC50: 0.06 µM) >ATP (EC50: 0.26 µM) 
P2Y14 UDP-glucose (EC50: 0.1–0.5 µM) 
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Figure 3: Adenosine receptor subtypes. A drawing.  
 
 
1.4. A1 adenosine receptors 
The human A1 receptor gene has been localised to the chromosome 1q32 
and codes for a 326 amino acid protein with a molecular weight of ~ 36.7 KDa 
(Olah and Stiles, 1995; Townsend-Nicholson et al., 1995); these receptors have a 
high affinity for adenosine and for adenosine analogues substituted at the N6 
position, for example L-N6-phenylisopropyladenosine (L-PIA) (Feostikov and 
Biaggioni, 1997). A1 receptors mediate the inhibition of adenylate cyclase, but can 
also inhibit G protein-coupled activation of voltage dependent Ca2+ channels and 
induce phospholipase C activation (Stiles, 1992); this adenosine receptor subtype 
is found in adipose tissue, heart muscle, central nervous system, airways and 
inflammatory cells such as neutrophils (Polosa, 2002). 
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1.5. A2 adenosine receptors 
On the contrary to the A1 receptor, A2 receptor stimulation leads to the 
activation of adenylate cyclase resulting in the elevation of intracellular cAMP 
(Olah and Stiles, 1995; Moreau and Huber, 1999). These receptors bind adenosine 
with less affinity than A1 receptors and are preferentially stimulated by adenosine 
analogues substituted at the 5’-N position, for example 5’-N-
ethylcarboxamideadenosine (NECA) (Livingston, 2004). A2 receptors are more 
widely distributed than A1 receptors, and are found in pre- and post-synaptic 
nerve terminals, mast cells, airway smooth muscle and circulating leukocytes 
(Polosa, 2002).  
A2 receptors are subdivided into the A2A and A2B receptors, based on high 
and low affinity for adenosine, respectively. In most cell types the A2A subtype 
inhibits intracellular calcium levels whereas the A2B potentiates them (Feostikov 
and Biaggioni, 1997). The human A2A receptor gene has been localised to the 
chromosome 22q11.2 and codes for a 337 amino acid protein with a molecular 
weight of 45 KDa (Le, 1996; Moreau and Huber, 1999); A2A receptors are 
expressed in the central nervous system, vascular smooth muscle, endothelium 
and on neutrophils, platelets, mast cells and T cells (Polosa, 2002). 
The A2B receptor, although structurally closely related to the A2A receptor 
and able to activate adenylate cyclase, is functionally very different. It has been 
postulated that this subtype may utilise signal transduction systems other than 
adenylate cyclase because of these functional differences (Polosa, 2002). The 
human A2B receptor gene has been localised to the chromosome 17p11.2-p12 and 
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codes for a 332 amino acid protein with a molecular weight of ~ 37.0 KDa (Olah  
and Stiles, 1995; Townsend-Nicholson et al., 1995). It has been identified widely 
including in the brain, human bronchial epithelium, endothelial cells, muscle cells, 
neurons, glial cells, fibroblasts and mast cells (Polosa, 2002). 
 
1.6. A3 adenosine receptors 
Similarly to the A1 receptor, stimulation of the A3 adenosine receptor leads 
to inhibition of adenylate cyclase (Olah and Stiles, 1995). It has also been shown 
to stimulate directly phospholipases C and D and experiments in HL-60 
promyeloid leukaemia cells have shown that A3 receptor activation results in the 
influx of calcium and its release from intracellular stores (Jacobson, 1998). The 
human A3 receptor gene has been localised to the chromosome 1p13.3 and 
consists of a 337 amino acid protein with a molecular weight of 36.0 - 37.0 KDa 
(Olah and Stiles, 1995; Moreau and Huber, 1999; Atkinson et al., 1997). In 
comparison with the other adenosine receptors, the A3 receptor exhibits large 
differences in structure, tissue distribution and its functional and pharmacological 
properties among species (Linden, 1994); furthermore, the possibility of two 
potential sub-types of A3 receptors has been raised (Jacobson, 1998). The A3 
receptor is widely distributed, being found in the kidney, testis, lung, mast cells, 
eosinophils, neutrophils, the heart and brain cortex (Polosa, 2002). 
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Figure 4: Adenosine receptor signalling pathways. The major signal transduction 
mechanisms; PLC, phospholipase C; MAPK, mitogen-activated protein kinase; CREB, 
cAMP response element binding; DAG, diacylglycerol; IP3, inositol 1,4,5-trisphosphate; 
PI3K, phosphatidylinositol 3-kinase; PIP2, phosphatidylinositol-4,5-bisphosphate; PK, 
protein kinase; PLD, phospholipase D; NF-kB, nuclear factor-kB. 
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Figure 5: Xanthines: structure. These natural products act blocking adenosine receptors. 
 
 
 
Figure 6: Adenosine A1 receptor agonists: structures 
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Figure 7: Adenosine A2 (a) and A3 (b) receptor agonists: structures. 
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Figure 8: Adenosine A1 (a) and A2A (b) receptor antagonists: structures. 
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Figure 9: Adenosine A2B (a) and A3 (b) receptor antagonists: structures. 
 
b 
a 
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2. ADENOSINE AND INFLAMMATION 
 
It has been known for a long time that inflammatory tissue damage is 
accompanied by accumulation of extracellular adenosine in inflamed areas due to 
its release from non-immune and immune cells (Sitkowsky, 2003); local tissue 
hypoxia in inflamed areas represents one of the most important conditions leading 
to adenosine release and accumulation (Winn et al., 1981; Van Belle et al., 1987; 
Rudolphi and Shubert, 1995), and also contributing to the accumulation of 
adenosine is the release of rapidly metabolized ADP and ATP from various cells 
including platelets, mast cells, and endothelial cells (Linden, 2001) (Figure 10). 
Investigations during more than three decades on the effects of adenosine on 
inflammatory processes and of the immunosuppressive properties of adenosine 
receptor-mediated signalling can be divided into two main periods: the first two 
decades provided the first demonstrations of the influence of extracellular 
adenosine on cells involved in the inflammatory response; the next two decades 
provided superior investigative tools and inquiries through the synthesis of novel 
ligands and molecular cloning of  adenosine receptor subtypes. It was shown that 
adenosine has both pro- and anti-inflammatory effects, and different adenosine 
receptors may have opposite effects on the same function; for example, neutrophil 
adherence to endothelium could be inhibited by A2A receptors and enhanced by A1 
receptors (Cronstein et al., 1992), and similarly mast cell degranulation could be 
inhibited by A2A receptors and enhanced by A2B receptors (Polosa, 2002). In 
contrast, A3 receptors could inhibit eosinophil migration and trigger degranulation 
of rodent mast cells; of special interest are the documented effects of adenosine on 
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secretion of pro-inflammatory cytokines, like IL-12 and TNF-α, by monocytes 
and macrophages (Hasko et al., 1996; Eigler et al., 1997). 
In conclusion, the current stage of inflammation and adenosine studies is 
characterized by utilization of molecules able to manipulate adenosine receptors 
and adenosine receptors signalling in different disease models, and also by the 
need to better understand the dual role of adenosine in the inflammatory 
responses. 
 
 
Figure 10: Adenosine, also a mediator of inflammation 
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2.1. The bases of inflammation 
Inflammation is characterized by five hallmarks: rubor (redness), tumor 
(swelling), calor (heat), dolor (pain) and functio lesa (loss of functionality); these 
symptoms result from recruitment, activation and interaction with tissues of 
immune cells including monocytes/macrophages, lymphocytes, mast cells, 
basophils, neutrophils, eosinophils and T-cells; the cellular component normally 
resides in blood and move into the damaged area via diapedesis;  acute 
inflammatory response is mediated by granulocytes, while chronic inflammation 
is mediated by mononuclear cells, such as monocytes and lymphocytes. 
Inflammation occurs at a site of infection or may be caused by non-infectious 
tissue insults, such as hypoxia, allergy, mechanical or thermal trauma. Usually, it 
is a very localized response that serves to refrain and eliminate the damaging 
agent and to repair the injured tissue; however, the normally beneficial immune 
arsenal is a cause of disease when it results in inappropriate and/or extensive 
injury to host tissues, in fact abnormalities associated with persistent 
inflammation comprise a large group of disorders which underly a variety of 
human diseases, including asthma, ischemic heart disease, autoimmune diseases, 
cancer.  
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2.2. The effects of adenosine on inflammatory cell function 
2.2.1. Neutrophils and adenosine 
Neutrophils are the body's first line of defence against pathogens and the 
destruction of pathogens mediated by these cells plays a crucial role in the early 
stages of the inflammatory and immune response; neutrophils are capable of 
releasing both adenosine and ATP (Cronstein et al., 1983); thus, their function is 
subject to autocrine and paracrine control by exogenous adenosine. All four 
adenosine receptor subtypes are expressed on neutrophils, and their expression 
further increases under inflammatory stimuli. Changes in A2 receptor expression 
on human neutrophils were found in some rheumatic diseases (Martini et al., 
1991). The effects of adenosine on neutrophil recruitment from the circulation 
were studied in many works; at submicromolar concentrations, adenosine 
enhances neutrophil adhesion to the vascular endothelium by stimulation of A1 
receptors on both neutrophils (Cronstein et al., 1992; Felsch et al., 1995) and 
endothelial cells (Zahler et al., 1994; Zahler and Becker, 1998), while at 
micromolar levels adenosine inhibits adhesion of neutrophils to vascular 
endothelial cells through A2A and A2B receptors expressed by neutrophils 
(Eltzschig et al., 2004; Sullivan et al., 2004); endothelial A3 receptors may also 
contribute to the adenosine-mediated inhibition of adhesion (Jordan et al., 1999). 
Neutrophil phagocytosis could be enhanced via A1 receptors and inhibited via A2 
receptors (Salmon and Cronstein, 1990; Zalavary et al., 1994; Zalavary and 
Bengtsson, 1998); moreover, it was recently demonstrated that A2A activation up-
regulates neutrophil cycloxygenase-2 (COX-2) expression and increases PGE2 
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generation, a prostaglandin with anti-inflammatory properties (Pouliot et al., 
2002; Cadieux et al., 2005). 
 
2.2.2. Monocytes/macrofages and adenosine 
  Mononuclear phagocytes are innate immune cells that reside in the 
bloodstream, as monocytes, or in various tissues, as macrophages; in contrast to 
neutrophils, which principally contribute to acute inflammatory responses, 
monocytes/macrophages are the major component of chronic inflammatory 
responses. Monocyte-like precursors colonize extravascular sites early during 
embryogenesis to become resident macrophages and acquire morphological and 
functional properties that are characteristic for the tissue in which they reside (for 
example, Kupffer cells in the liver, microglial cells in the brain). During postnatal 
life, circulating monocytes are capable of migrating into various tissues in 
response to damage or infection, where they transform into macrophages, which 
are the major source of inflammatory mediators during inflammatory and immune 
responses. All four adenosine receptor subtypes are expressed by both monocytes 
(Thiele et al., 2004) and macrophages (Nemeth et al., 2005), but receptor 
expression appear to change during maturation; whereas expression of the A1, A2 
and A3 receptor subtypes is relatively low in quiescent monocytes (Sajjadi et al., 
1996; Fossetta et al., 2003), the expression of these receptors increases during 
differentiation into macrophages (Sajjadi et al., 1996; Thiele et al., 2004). 
Extracellular adenosine may affect monocyte adhesion during inflammation 
modulating adhesion molecule expression on endothelium, and several in vivo 
findings support a regulatory role for extracellular adenosine in adhesive 
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interactions between monocytes and the vascular endothelium (Bours et al, 2006). 
Many studies investigated the effects of adenosine on cytokine production by 
monocytes/macrophages; it has been shown that adenosine inhibits production of 
the potent pro-inflammatory cytokines IL-12 and TNF-α via multiple receptors, 
like A2A, A2B and A3 receptors, and as shown in murine macrophages, adenosine 
inhibits LPS-mediated production of IFN-γ via A3 receptors (Hasko et al., 2000). 
Macrophages phagocytosis is enhanced through A1 receptors activation and 
inhibited through A2 receptors (Salmon et al., 1993); furthermore, extracellular 
adenosine affects both RNS (reactive nitrogen species) and ROS (reactive oxygen 
species) production by monocytes/macrophages. 
 
2.2.3. Lymphocytes and adenosine 
Lymphocytes are central to humoral and cellular immune responses; B 
lymphocytes, originating from the bone marrow, mediate humoral immunity by 
producing antibodies that neutralize and eliminate extracellular pathogens; T 
lymphocytes are mediators of cell-mediated immunity directed against 
intracellular pathogens. Thymus-derived T lymphocytes are usually subclassified 
in CD4 expressing Th cells, which  orchestrate immune responses by secreting 
multiple cytokines, and CD8 expressing cytotoxic T cells (CTLs), which are able 
to recognize and kill infected cells through either exocytosis of cytotoxic granule 
proteins or apoptosis-inducing membrane-bound proteins and with functions 
resembling those of natural killer (NK) cells, which are an additional class of 
lymphocytes participating in innate defence mechanisms. Adenosine seems to 
play an important role on modulation of T lymphocytes function; both peripheral 
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CTLs and Th cells express A2A, A2B and A3 receptors, but A2A receptors are 
proposed to be the predominantly expressed in peripheral T lymphocytes (Huang  
et al., 1997; Koshiba et al., 1999); probably,  extracellular adenosine effect on 
these cells is mediated through A2A receptor (Bours et al, 2006). It has been 
shown that adenosine at micromolar levels (50 µM) promotes vascular barrier 
function and inhibits lymphocytes transmigration (Henttinen et al., 2003); 
moreover, cytokine production by activated Th cells is modulated by extracellular 
adenosine through A2A receptors (Koshiba et al., 1999), and it was demonstrated 
that TCR (T-cell receptor)-mediated activation of murine T cells induce a rapid 
up-regulation of functional A2A receptors and the signalling of the up-regulated 
A2A receptors inhibit IFN-γ release by these cells (Lappas et al., 2005). On the 
contrary, little is known about the influence of adenosine receptors on the function 
of B lymphocytes and NK cells, but it is known that B lymphocytes express A1 
and A2A receptors, while NK cells express A1, A2A and A3 receptors, and NK cell 
cytolytic function is enhanced by extremely low concentrations of A1 receptor 
agonists and inhibited by A2A receptor agonists (Priebe et al., 1990). 
 
2.2.4. Mast cells and adenosine 
Mast cells are necessary during inflammation for the development of 
allergic reactions, through cross-linking of their surface receptors for IgE (Fc RI), 
leading to degranulation and the release of vasoactive, pro-inflammatory and 
nociceptive mediators that include histamine, cytokines and proteolytic enzymes, 
while these cells are rarely seen to degranulate during auto-immune or non-
immune inflammatory processes. Adenosine receptors are expressed on mast cells 
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but the exact pattern of receptor subtype expression depends on the source of the 
mast cells (human, murine, rat, etc.), so it is not unsurprising that adenosine 
effects on mast cells differ among species depending on the receptor involved, on 
the receptor expression level and on the concentration of adenosine in the tissue. 
An early work demonstrated that adenosine potentiates histamine release induced 
by antigen and other non-immunological stimuli, including compound 48/80 and 
calcium ionophore, from rat peritoneal mast cells (Marquardt et al., 1978); it was 
also shown that adenosine enhanced the histamine release and prolonged the 
cAMP response in purified rat peritoneal mast cells following immunological 
challenge suggesting an A2 receptor mechanism (Church et al., 1985; Church and 
Hughes, 1985), but also A3 receptors are probably responsible for enhancing the 
release of mast cell mediators (Linden et al., 1993; Salvatore et al., 1993). Several 
more recent studies in animal models (Tigani et al., 2000; Tilley et al., 2000) 
suggest that adenosine can directly activate mast cells in vivo in the absence of 
additional stimuli. It has been supposed that adenosine acts bi-modally on human 
lung mast cells suppressing histamine release at low concentration via A2A 
receptors and enhancing histamine release at high concentration via A2B receptors 
(Polosa, 2002). 
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3. ADENOSINE AND ASTHMA 
 
Evidence for adenosine’s role in bronchial asthma was first demonstrated 
more than twenty years ago when a group of asthma patients exhibited 
bronchoconstriction in response to aerosolized adenosine while normal 
individuals didn’t display response (Cushley et al., 1983). Adenosine levels are 
increased in the bronchoalveolar lavage (BAL) fluid of asthmatics compared to 
normal subjects, suggesting there is an imbalance in the homeostatic mechanisms 
involved in purine metabolism (Driver et al., 1993); furthermore, adenosine levels 
are increased in the lung lavage fluid after specific allergen challenge in sensitised 
rabbits (Ali et al., 1991). Inhalation of allergen in atopic asthmatics increases 
adenosine plasma levels  up to 3-fold (Mann et al., 1986); in asthmatic and non-
asthmatic subjects adenosine plasma levels increase in response to exercise, but 
the response is  significantly greater in atopic asthmatics (Vizi et al., 2002); 
elevated concentrations of adenosine in the lungs of adenosine deaminase-
deficient mouse models have produced a lung phenotype with features of asthma 
(Blackburn et al., 2000; Chunn et al, 2001; Zhong et al., 2001). 
The specific cellular source of adenosine in bronchoalveolar lavage fluid is 
unknown, but is likely to include mast cells along with epithelial cells, neutrophils 
and platelets (Livingston et al., 2004). 
 
3.1. Bronchial asthma physiopathology 
Asthma is a chronic pulmonary disease characterized by acute 
exacerbations of coughing, dyspnoea, wheezing and chest tightness; patients 
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usually have reduced forced expiratory volume in one second (FEV1) as well as 
reduced airflow. Characteristic features of asthma are airway inflammation and 
bronchial hyperresponsiveness (Bousquet et al., 2000). Heightened airway 
responsiveness to a wide variety of pharmacological and physical agents is typical 
of asthma, and the degree of airway responsiveness usually correlates with the 
severity of the disease (Hargreave et al., 1980). A listing of clinical findings in 
asthma is given in Table 3; severity of asthma is based on the frequency and 
intensity of symptoms. The mildest grade is characterized by acute attacks upon 
allergen exposure, and with symptoms reversed by β-adrenergic agonists 
(Linssen, 1991); lung function is normal between acute attacks. More severe 
grades of asthma are characterized by sustained increase in airway resistance (the 
late-phase response), impaired basal lung function and heightened airways 
responsiveness to non-specific irritants (hyperreactivity); cellular inflammation is 
common and comprised of increased number of mast cells and eosinophils in the 
bronchial mucosa (Dunnill, 1960); the inflammation is believed to contribute both 
to the late-phase response and to the heightened airway reactivity. 
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Table 3: Clinical findings in bronchial asthma (adapted from Karol M.H. et al., 1994). 
Coughing, wheezing, dyspnoea 
Chest tightness 
Airflow disturbance, occurring either immediately following or hours after 
exposure to allergen 
Impaired basal lung function (in severe cases) 
Bronchial hyperreactivity to pharmacological agents 
Eosinophilic airway inflammation 
Increased mast cells in the bronchial mucosa 
Activated T-cells in the bronchial mucosa 
Elevation of serum IgE, both antigen-specific and total 
 
 
Figure 11: Asthma physiopathology. A scheme of stimuli, cells and molecules involved and 
their effects.
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Asthma appears to be under the influence of both genetic and 
environmental factors. Based on the relationship between airway hyperreactivity 
and serum immunoglobulin E (IgE) (Burrows et al., 1989; Sears et al., 1991), it 
has been suggested that asthma has always an atopic component, where atopy is 
defined as the presence of elevated IgE (two-thirds of patients with asthma result 
atopic by skin tests) (Smith, 1988). Familial studies have provided evidence for a 
genetic component in development of allergy, and inheritance of atopy appears to 
be dominant and associated with a specific gene on the short arm of chromosome 
11, and linkage is expressed predominantly through the mother; genes derived 
from the father appear not to be expressed (Young et al., 1992). Environmental 
exposure to the offending allergen is necessary for the expression of genes to the 
allergen and the level of allergen exposure governs the expression of the gene(s) 
(Holgate, 1993). Sensitization appears to be favoured when exposure to allergen 
occurs in presence of irritants, such as pollutants, or with upper respiratory viral 
infections, but the mechanism of this environmentally contributed adjuvant 
activity is unclear, it has been hypothesized to occur through inflammation and 
enhanced penetration of allergen through mucosal barriers (Holt, 1989). 
Estabilished the pivotal role of environmental and genetic factors in the 
disease process, the pathogenic mechanisms of bronchial asthma remain unclear, 
although it is currently the most prevalent respiratory disease. Convincing 
evidence has been presented for humoral immunological aetiology of the early-
onset response; this response is believed to result from mediators released by 
activated granulated cells, such as mast cells (Holgate, 1993). The rapid response 
is reversed by β2-agonists, and probably results from contraction of airway smooth 
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muscles, which present receptors for the released mediators; the crosslinking of 
mast cell-bound IgE is followed by cytokine release (including tumour necrosis 
factor-α (TNF-α) and interleukin-4 (IL-4) from cells. Mast cells are also believed 
to have a central role in the subsequent inflammatory process: they are effector 
cells containing ready-to-release granules, and mediators released from this cell 
type can cause bronchial smooth muscle contraction, and induce migration of 
neutrophils and eosinophils to the site of degranulation; compounds preventing 
mast cell degranulation, like sodium cromoglycate and nedocromil sodium, have 
long been in use as asthma treatments (Kelly et al., 2001).  
The late-phase response is characterized by inflammation; increased 
numbers of inflammatory cells are found among the epithelial cells and these 
include intact and degranulated eosinophils, lymphocytes, activated macrophages 
and partly degranulated mast cells (Laitinen et al., 1985; Gibson et al., 1993; 
Poston et al., 1992; Pesci et al., 1993). T-cells appear to have a fundamental role 
in the inflammation: many features of the late-phase response, including 
eosinophilia, mast cell activation and IgE production, appear to be regulated by T-
lymphocytes that probably regulate inflammation through production of 
cytokines, such as IL-4 and IL-5.  Atopic asthmatics have been found to possess 
activated T-cells in their airways (Robinson et al., 1992); additional evidence of 
T-cell regulation of the inflammatory response has been obtained from animal 
studies (Iwamoto et al., 1993). Recently, it has been demonstrated that goblet cell 
hyperplasia precedes the inflammatory infiltrate and persists even after the 
number of inflammatory cells decreases, indicating that some of the phenotypic 
changes in airway epithelium are not caused by inflammation (Blyth et al., 1996). 
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In asthma, remodelling is almost always present in biopsies, as shown by collagen 
deposition on the reticular basement membrane, but is not always clinically 
demonstrated, while the destruction and subsequent remodelling of the normal 
bronchial architecture are manifested by an accelerated decline in FEV1; this 
irreversible component of the airway obstruction is more prominent in severe 
patients and even persists after an aggressive treatment (Bousquet et al., 2000). 
Animal models are typically developed for either elucidating pathogenic 
mechanisms of bronchial asthma and/or testing new antiasthmatic drugs, in fact 
they are necessary to permit prediction of the efficacy of new chemicals before the 
latter reach large scale production; animal models have been able to reproduce 
several symptoms and features (airway hyperresponsiveness, elevated IgE or other 
anaphylactic antibody class, pulmonary eosinophilia, mast cell and/or eosinophil 
derived products in the bronchial mucosa or bronchoalveolar lavage, 
diaphragmatic contractions, cyanosis, lung resistance, microvascular leakage of 
proteins, elevated ratio of interleukin-4 and/or interferon-γ, increased airway 
resistance, abnormal airflow, airway mucus and airway smooth muscle 
hypertrophy), reproducing both the acute airway spastic response associated with 
asthma, as well as the late-onset inflammatory reactions. Animal models can be 
particularly effective in elucidating factors associated with development of airway 
sensitivity and expression of responses, enabling identification of the importance 
of antigen dose (or extent of antigen exposure) to the processes of sensitization 
and elicitation of responses (Karol et al., 1987; Karol, 1983), and they are ideally 
suited to investigation of the role of environmental factors and of genetic 
predisposition in development of asthma. With all the benefits to be derived from 
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the development and use of animal models for study of asthma, there exist 
caveats: attention must always be given to identify differences between animal 
and human systems; anatomical, physiological and biochemical differences exist 
between species. Characteristics, such as airway morphometry, breathing patterns, 
innervation of respiratory tract tissue, and circulation to the lung, are critical to 
sensitization and to asthma; these factors, along with immunological components, 
must be considered in the evaluation of an animal model. 
 
3.2. Adenosine-induced bronchoconstricition 
Bronchoconstrictor responses to adenosine have been studied in humans, 
guinea pigs, rabbits and rats. In general, normal guinea pigs and rabbits do not 
respond to inhaled adenosine and only sensitised guinea pigs and allergic rabbits 
show bronchoconstrictor responses; the responses of rat airways to adenosine in 
vivo are very much dependent on the strain of rat but are usually markedly 
increased hours after sensitisation of the airways with allergen (Fozard and 
Hannon, 2000). Inhalation of aerosolised adenosine (or the more soluble AMP) 
results in bronchoconstriction in allergic and non allergic asthmatic human 
subjects. This airway response, confirmed also following intravenous adenosine 
administration (Drake et al., 1994), is not seen in non atopic non asthmatic 
subjects, but atopic non asthmatic subjects show a variable response with some 
demonstrating bronchoconstriction (Cushley et al., 1983; Cushley et al., 1985).  
Guanosine (a structurally related molecule) and inosine (an adenosine 
metabolite) have no effect on airway calibre suggesting that the response is 
specific to adenosine; ADP and AMP are equipotent in terms of 
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bronchoconstriction (Mann J.S. et al., 1986), and instillation of AMP directly into 
the airway segment of asthmatics via the bronchoscope has been shown to cause a 
rapid reduction of airway calibre, which is paralleled by the release of histamine, 
tryptase, and PGD2 (Finney et al., 1985).  
Interestingly, significant (2–3-fold) increases in circulating adenosine 
levels (but not inosine) were reported after inhaled allergen and methacholine 
challenge in atopic asthmatics (Mann et al., 1986); the kinetics of the observed 
increases in plasma adenosine after challenge were similar for allergen and 
methacholine, despite dissimilar time courses for airflow obstruction. Allergen 
induced increase in plasma adenosine (2–5 min after provocation) continued to 
rise in parallel with the onset of bronchoconstriction; with methacholine, plasma 
adenosine concentrations continued to rise up to 30 min after provocation, long 
after peak bronchoconstriction (5 min) and when the airway was starting to 
recover. 
Dipyridamole, an adenosine uptake inhibitor, has been shown to enhance 
adenosine-induced bronchoconstriction in asthmatic subjects suggesting a cell 
surface receptor-mediated mechanism (Crimi et al., 1988). Further evidence came 
from work showing that theophylline (an adenosine receptor antagonist) provided 
protection against adenosine-induced bronchoconstriction; this protection was 2–5 
times greater than that produced against histamine-induced bronchoconstriction 
(Cushley et al., 1984; Mann et al., 1985). 
Mechanisms underlying bronchoconstriction have been explored by 
several in vitro and in vivo studies but results were often conflicting due mainly to 
differences in bronchial response among species and to differences in the basal 
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tone of airway smooth muscle (Polosa et al., 2002). In vitro, adenosine weakly 
contracts human and guinea-pig airways maintained at basal tone but relaxes 
guinea pig airways pre-contracted with carbachol (Advenier et al., 1982; Finney  
et al., 1985), and it has been observed that contraction induced by adenosine is 
more marked in isolated airway from asthmatics than non asthmatics (Bjorck et 
al., 1992). 
Several studies suggest that the bronchial response to adenosine is not due 
to a direct effect, but most likely to mast cell degranulation; a first correlation 
between adenosine receptors and mast cells was already observed in 1978 when 
Marquardt reported that adenosine, although ineffective alone, potentiated 
histamine release induced by anti-immunoglobulin E, concanavalin A, compound 
40/80 and by the calcium ionophore A23187 in isolated rat mast cells (Marquardt  
et al., 1978). Given the role of mast cells in asthma, the involvement of adenosine 
receptors in mast cell degranulation has raised great interest and has been widely 
explored. In vitro studies indicate that adenosine enhances the release of histamine 
and other preformed mediators from immunologically primed rodents mast cells 
(Marquardt and Wasserman, 1982); the increase of histamine release from rat 
peritoneal mast cells is insensitive to methylxanthines thus suggesting that this 
process might be mediated by a receptor with low affinity for xanthines, such as 
the adenosine A3 receptor (Zhou et al., 1992). It is important that biochemical 
characteristics of mast cells and response to pharmacological agents can vary 
among species and among anatomical sites and there is recent evidence that 
adenosine A2B receptors mediate the release of inflammatory mediators. 
Adenosine is able to increase mediator release from human mast cells obtained 
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with mechanical dispersion or enzymatic dispersion of lung, with leukotriene C4 
that is one of these mediators (Peachell et al., 1988), and same results have been 
shown on mast cells obtained from bronchoalveolar lavage (Forsythe et al., 1999). 
In parenchymal human lung mast cells obtained from surgical specimens, 
adenosine does not induce the release of histamine directly, but only when mast 
cells are immunologically activated (Peachell et al., 1991). Evidence for a role of 
mast cells in bronchoconstriction induced by adenosine is also available from in 
vivo studies; inhalation of AMP in asthmatics increases circulating levels of 
histamine (Phillips et al., 1990). Agents blocking mast cells degranulation, such as 
sodium cromoglycate and nedocromil sodium, inhibit bronchoconstriction 
induced by AMP in asthmatics and, in addition, pre-medication with the H1 
histamine receptor antagonists, terfenadine and astemizole, inhibits 
bronchoconstriction induced by AMP in the asthmatic subjects (Rafferty et al., 
1987; Richards et al., 1988; Phillips et al., 1989a; Phillips et al., 1989b). 
Instillation of AMP in asthmatic bronchi or in the nose of patients with allergic 
rhinitis increases histamine and tryptase concentrations in the lavage fluid (Polosa  
et al., 1995; Polosa et al., 1999), whereas inhaled heparin, by means of inhibition 
of mast cells activation, attenuates airway response to AMP (Polosa and Holgate, 
1997) and the response induced by nasal provocation with AMP (Zeng et al., 
2004). Adenosine also stimulates the release of other mediators from mast cells, 
including prostanoids, since bronchoconstriction induced by AMP is attenuated by 
indomethacin, flurbiprofen and lysine acetylsalicilate (Phillips et al., 1989a; 
Phillips et al., 1989b; Crimi et al., 1995). Increased concentration of prostaglandin 
D2 has also been found in bronchoalveolar lavage after instillation of adenosine 
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(Polosa et al., 1995); furthermore, a role for cysteinyl-leukotrienes in AMP-
induced bronchoconstriction has also been suggested since montelukast, a 
leukotriene receptor antagonist, attenuates acute AMP-induced 
bronchoconstriction (Rorke et al., 2002). 
Activation of neural pathways (cholinergic and peptidergic) is suspected to 
contribute to the contractile airway response to adenosine; the involvement of 
cholinergic reflexes has been supposed following the observation that in rat and in 
man inhaled ipratropium bromide attenuates bronchoconstriction induced by AMP 
(Polosa et al., 1991). The neural contribution to AMP-induced 
bronchoconstriction is also suggested by the observation that inhaled furosemide 
and bumetanide, loop diuretics modulating sensory nerve responses in the 
airways, inhibit bronchial response to AMP (O'Connor et al., 1991; Polosa et al., 
1993). Furthermore,  in guinea-pigs in vivo bronchoconstriction induced by 
adenosine is attenuated by treatment with capsaicin,  a sensory nerves depleting 
agent (Manzini and Ballati, 1990). The role of neuropeptides in adenosine-
induced bronchoconstriction is also  supported by the observation that repeated 
challenges with inhaled bradykinin (a model of neuropeptides depletion in human 
airways) attenuate the bronchial response to adenosine (Polosa et al., 1992), and it 
was proved that in rat pulmonary circulation adenosine induces vasoconstriction 
by activation of neuropeptides-producing nerves (Meade et al., 1996). Recently it 
has been speculated that, since both bradykinin B2 and adenosine receptors have 
been identified on mast cells and on peptidergic nerves, adenosine and bradykinin 
may share a common activation pathway through the release of neuropeptides 
known to activate mast cells (Rajakulasingam et al., 1994; Holgate, 2005). 
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However, inhibition of neutral endopeptidase (NEP) induced by inhaled 
phosphoramidon failed to elicit any significant enhancement of the bronchial 
response to AMP, suggesting that release of endogenous neuropeptides has little 
importance in the airway response to adenosine (Polosa et al., 1997). 
After all, it was speculated that in asthma adenosine stimulates mast cells 
to degranulate and to release histamine, which causes an additive effect through 
vagal nerve stimulation (Polosa, 2002); but although adenosine-induced mast cell 
degranulation is an important component of the airway response to adenosine, it is 
likely not the complete mechanism, and so further investigation is required.  
More recent publications have also used AMP as a bronchoprovocant (Lee et al., 
2004; Luijk et al., 2004; Zeng et al., 2004), as it is rapidly broken down to 
adenosine and is more soluble than the parent nucleoside alone but with the same 
effect (Mann et al., 1986); this selectivity makes it an attractive target for 
diagnostics, in fact measuring bronchoconstriction with inhaled AMP provides a 
useful and non invasive means of diagnosis (Van den Berge et al., 2004a). In 
addition, recent evidence suggest that bronchial challenge with inhaled AMP may 
be an useful tool to asses and monitor airway inflammation; bronchial 
hyperresponsiveness to AMP correlates better than bronchial hyperresponsiveness 
to histamine or methacholine (the two most commonly used agents to assess 
bronchial hyperresponsiveness) with markers of airway inflammation such as 
sputum, blood and bronchial tissue eosinophilia and exhaled nitric oxide (eNO) 
(van den Toorn et al., 2001; De Meer et al., 2002; Van den Berge et al., 2004b). 
Control of airway inflammation is a major target of the pharmacological treatment 
in asthma, and if changes in bronchial response to AMP reflect fine changes in 
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airway inflammation, bronchial challenge with AMP would provide an excellent 
tool to follow these changes and to assess the efficacy of the anti-inflammatory 
treatment. In fact, early studies have shown that regular treatment with inhaled 
steroids reduces airway response to AMP as compared to methacholine (O'Connor 
et al., 1992; Wilson and Lipworth, 2000), while more recently it was shown that 
in asthmatics bronchial response to inhaled AMP is sensitive to  inhaled steroid 
budesonide after one week treatment; whereas, changes in bronchial response to 
methacholine together with changes in percentage eosinophil and epithelial cell 
counts in the sputum can be observed only by the fourth week of treatment 
(Prosperini et al., 2002). 
 
3.3. Adenosine and airway inflammation 
A great amount of works has been done in the last decade to understand 
the functional role of adenosine in airway inflammation and the involvement of 
this nucleoside in several aspects of inflammation, such as recruitment of 
inflammatory cells, release of inflammatory mediators, airway remodelling and 
mucus secretion. Above all, endogenous released adenosine is a potent regulator 
of airway inflammation, particularly of allergic inflammation; human lung in vitro 
releases adenosine upon stimulation with allergens in presence of inhibitors of 
adenosine deaminase (Konnaris et al., 1996). In atopic asthmatics bronchial 
challenge with allergens increases blood levels of adenosine (Mann et al., 1986) 
and exercise-induced bronchoconstriction is also followed by an increase in 
circulating adenosine levels (Vizi et al., 2002); increase in adenosine 
concentration was also found in the bronchoalveolar lavage of patients with 
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asthma. In addition to increase mast cells activation, adenosine promotes release 
of inflammatory cytokines from human monocytes (Le Vraux et al., 1993) and 
smooth muscles, leukocytes chemotaxis via adenosine A2B receptors and 
eosinophils recruitment and activation via adenosine A3 receptors (Young et al., 
2004). The development of non-invasive techniques to assess airway 
inflammation, such as evaluation of soluble mediators in exhaled breath, has 
further confirmed the involvement of adenosine in airway inflammation. In fact, 
increased levels of adenosine have been found in exhaled breath condensate of 
steroids-naive asthmatics as compared to healthy subjects and steroids treated 
patients (Huszar et al., 2002); adenosine levels also increase in exhaled breath 
condensate during exercise-induced bronchoconstriction in asthmatics, but not in 
healthy subjects (Csoma et al., 2005). 
Although the precise source of adenosine release (mast cells, smooth 
muscle, epithelial cells) remains uncertain, it is likely that adenosine may 
contribute to the bronchoconstriction induced by other bronchoprovocants such as 
allergens (Huszar et al., 1998); it is well known that adenosine potentiates the 
release of inflammatory mediators when human mast cells are immunologically 
primed (Peachell et al., 1991) and therefore it has been recently emphasized the 
link between airway response to adenosine and the state of atopy; in fact, a 
number of studies indicate that atopic asthmatics are significantly more responsive 
to inhaled AMP than non atopic asthmatic (Spicuzza et al., 2003).  
The notion that inflammatory cytokines can regulate adenosine receptors 
expression (Khoa et al., 2001; Xaus et al., 1999) further suggests a role for 
adenosine in the inflammatory environment; furthermore, in transgenic animals 
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the severity of airway inflammation and lung remodelling is amplified by the 
release of adenosine (Blackburn et al., 2003), confirming that this mediator might 
serve a regulatory role in lung inflammatory diseases. It was recently investigated 
on adenosine receptors and cell types mediating the pro-inflammatory and anti-
inflammatory effect of adenosine in the lung by the means of an amino deaminase 
deficient model of mice (Tilley and Boucher, 2005); in this model, inflammatory 
effects of adenosine are mediated by the A3 receptors involved in mast-cell 
dependent increase in vascular permeability, adenosine-induced mast cells 
degranulation, antigen-induced mast cells degranulation, mucus secretion and 
recruitment of inflammatory cells in the lung. A2B receptors also contribute to 
mast cells degranulation, while A1 and A3 receptors present on macrophages 
mediate the antiinflammatory effects of adenosine through an increase in the 
release of anti-inflammatory mediators (IL-10 and PGE2) and inhibition in the 
release of pro-inflammatory mediators (TFN-α and matrix metalloproteinase). 
There is opinion that adenosine accumulation in the lung is not only a 
product of lung inflammation and damage, but can directly affect signalling 
pathway that lead to features of chronic lung disease (Blackburn, 2003). Some 
authors have speculated that the pro- and anti-inflammatory properties of 
adenosine may be dictated by its level in the lung: in the initial stage, low levels 
of adenosine would activate high affinity receptors, such as adenosine A2A 
receptors, triggering a protective pathway, but when lung inflammation is severe, 
high levels of adenosine release would activate the low affinity adenosine A2B 
receptors triggering injurious signaling pathways that further exacerbate 
inflammation (Polosa et al., 2000; Blackburn, 2003). 
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Following evidence on the role of adenosine in inflammation, it has been 
suggested that targeting adenosine receptors might be a valuable approach for the 
development of antiinflammatory treatments in diseases characterized by chronic 
airway inflammation, such as asthma. Although some selective agonist/antagonist 
are currently under development, one major problem is to establish which 
receptor/s should be targeted; indeed, distinct pro- and anti-inflammatory 
functions of adenosine are likely to be dependent on the dynamic regulation of 
specific adenosine receptors on specific cell types in a given inflammatory 
environment; moreover, as yet said, adenosine receptors are widely spread in 
human body, therefore a selective targeting of the site of action should be granted. 
 
3.4. Adenosine receptors in airways 
In the respiratory system all four adenosine receptors are expressed, and 
these are present on inflammatory/immune cells (mast cells, macrophages, 
lymphocytes, fibroblasts, eosinophils and neutrophils) recruited into the site of 
inflammation as well as in some structural components of lungs, such as airway 
smooth muscle, epithelium and secretive cells (Polosa et al., 2002) (Figure 12). 
It is now clear that the variety of cellular responses induced by adenosine 
in airways are mostly mediated through interaction with its receptors on the 
surface of target cells (Olah and Stiles, 1995). The ability of the adenosine uptake 
inhibitor, dipyridamole, to enhance adenosine-induced effects leads to the 
suggestion that its actions are likely to be mediated through stimulation of specific 
cell surface located receptors  (Stafford, 1966; Crimi et al., 1988); in addition, 
theophylline, a drug that is frequently used for resolution of airway obstruction in 
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asthma, is known to attenuate adenosine-induced bronchoconstriction through an 
adenosine receptor antagonistic activity at therapeutic plasma levels (20-120 mM) 
(Polosa, 2002). In the early '80s, understanding of adenosine receptors was simply 
based on the activity of "specific" agonists/antagonists and limited to a division 
between A1 receptors (which decreased intracellular cyclic AMP (cAMP) levels) 
and A2 receptors (which increased intracellular cAMP) (Van Calker et al., 1979; 
Londos et al., 1980). Suggestion that the adenosine A1 receptor antagonistic 
activity of theophylline might explain its clinical potency fell down when it was 
discovered that another xanthine, enprofylline, was clinically  effective as 
theophylline although devoid of adenosine A1 receptor antagonistic activity. 
Enprofylline was also able to block adenosine-induced bronchospasm in asthmatic 
subjects and, despite its lack of A1 receptor antagonistic activity, was more potent 
in this respect than theophylline; this paradox, named “enprofylline paradox”, was 
at that time considered to be  evidence against adenosine receptor antagonism as 
an explanation of the clinical efficacy of xanthines. In the ’90s, information about 
new adenosine receptor subtypes provided a possible explanation for the 
enprofylline paradox, in fact the application of molecular cloning techniques has 
expanded the range of known adenosine receptors to include the A3 receptor  
(Salvatore et al., 1993) and the A2B receptor, whereas the originally described A2 
receptor now was designated A2A (Pierce et al., 1992). Enprofylline (as well as 
theophylline) inhibits ligand binding to the human recombinant adenosine A2B 
receptor with a Ki of  ~ 7 mM (Robeva et al, 1996; Linden et al., 1999), a value 
which lies within the typical plasma levels of enprofylline (5–25 mM) after 
therapeutic dosage. However, the fact that enprofylline has little affinity with the 
 48 
A1 receptor does not mean that the A1 receptor has not any role in asthma; indeed, 
an antisense oligonucleotide against the adenosine A1 receptor was under 
investigation for asthma therapy (Metzger and Nyce, 1999).  
Description of adenosine A1 receptor expression and distribution has been 
widely carried out in mammals; binding data indicate that  A1 receptor is not 
particularly abundant in normal human lung, but its presence, possibly associated 
with nerves, is supported by functional studies; this subtype is also present on 
human neutrophils, its activation promotes chemotaxis (Cronstein et al., 1990) 
and increases adherence to endothelial cells (Cronstein et al., 1990; Felsch et al., 
1995). With specific regard to asthma, it was shown that rabbits immunised at 
birth with antigen develop airways hyperreactivity to adenosine by a mechanism 
involving upregulation of A1 receptor (Ali et al., 1994; el-Hashim et al., 1996). 
Successively, in an elegant extension of these studies, using rabbits engineered 
with an antisense oligo-deoxynucleotide (ODN) targeted against adenosine A1 
receptors of the lung to reduce their numbers, it was confirmed that adenosine-
mediated bronchoconstriction is mediated by this receptor subtype (Nyce and 
Metzger, 1997). An early study showed that in the airways of non asthmatic 
subjects there was not evidence of A1 adenosine receptors (Joad and Kott, 1993); 
conversely, another study shown that adenosine–induced contraction of isolated 
bronchi from asthmatic patients was mediated, via adenosine A1 receptors, by 
histamine and leukotrienes (Bjorck et al., 1992). More recently, studies performed 
with radiobinding ligands have shown the presence of A1 adenosine receptors on 
cultured human airway smooth muscle cells (Zhong et al., 2004); moreover, 
elevated transcript levels for adenosine A1 receptor, particularly in alveolar 
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macrophages, were found in a model of amino deaminase-deficient mice, and 
genetic removal of these receptors resulted in an increased lung inflammation and 
injury with mucus metaplasia and alveolar destruction (Sun et al., 2005). 
According to this evidence, adenosine A1 receptor seems to play a dual role in the 
lung probably due to the pattern of its distribution; however, its role in asthma is 
still unclear. 
Both A2A and A2B receptors have been identified by reverse-transcriptase 
polymerase chain reaction (RT-PCR) on human bronchoalveolar lavage mast cells 
(Feoktistov and Biaggioni, 1998; Suzuki et al., 1998); the subunits of G protein 
(Gs) coupled adenosine A2A and A2B receptors are distinguished by their high and 
low affinity, respectively, for adenosine (Feoktistov et al., 1998). The A2A 
receptors most relevant to human lung disease are those expressed on mast cells 
(Feoktistov and Biaggioni, 1998; Suzuki et al., 1998), neutrophils (Varani et al., 
1998) and T-cells (Varani et al., 1997). In contrast to A2B receptors, A2A activation 
results in suppression of histamine and tryptase release from human mast cells 
(Hughes et al., 1984; Peachell et al., 1991; Suzuki et al., 1998), and this could 
provide a balanced control mechanism, because it is possible that at low 
concentrations of adenosine, only the cellular signalling provided by engagement 
of the high affinity A2A receptors prevails, thus down-regulating mast cell 
mediator release, and conversely, in situations in which high concentrations of 
adenosine are reached, such as in asthma (Driver et al., 1993), the relative 
importance of the low-affinity A2B receptor becomes greater with significant mast 
cell degranulation. In addition, it is well known that stimulation of A2A receptors 
reduces neutrophil adherence to the endothelium (Cronstein et al., 1992), prevents 
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upregulation of integrin expression on FMLP (N-formyl-methionyl-leucyl-
phenylalanine) stimulated neutrophils (Wollner et al., 1993) and inhibits 
degranulation of activated neutrophils and monocytes (Bouma et al., 1994; 
Fredholm et al., 1996; Hannon et al., 1998). A first evidence of the potential 
antiinflammatory role of adenosine A2A receptors in airways derives from a study 
in an in vivo model of airway inflammation in which inhibition of leukocytes 
accumulation induced by methrotrexate is blocked by the selective adenosine A2 
receptor antagonist DMPX (Cronstein et al., 1993). More recently, it has been 
shown that, in sensitised Brown Norway rats, the inflammation induced by 
ovalbumin, consisting of an increase in leukocytes, protein content and 
eosinophils peroxidase activity in bronchoalveolar fluid, was dose-dependently 
inhibited by the adenosine A2A receptor agonist CGS21680, and this effect was 
similar to that obtained with the glucocorticoid budesonide (Fozard and 
McCarthy, 2002). Administration of an A2A receptor agonist therefore exhibited 
antiinflammatory potential in a disease such as asthma, where inflammation is 
strongly implicated, but unfortunately these receptors have a broad anatomical 
distribution with many effects through the body, including inhibition of platelet 
aggregation, vasodilatation and a variety of effects on the central nervous system 
(Ledent et al., 1997); these side effects represent the major limitation for the 
introduction of similar compounds in clinical trials, and so a selective topical 
action in the lung is required. 
Adenosine A2B receptors, as yet shown,  display a lower affinity for 
adenosine and agonists, as compared to adenosine A2A receptors. Although 
similarities in their structure and ability to increase intracellular cAMP have been 
 51 
shown, the functional role of the two receptors is different, probably due to the 
fact that adenosine A2B receptors can activate other intracellular pathways in 
addition to cAMP; actually,  in contrast to A2A receptors, stimulation of A2B 
receptors can activate phospholipase C in human mast cells and in mouse bone 
marrow-derived mast cells (Marquardt et al., 1994; Feoktistov and Biaggioni, 
1995). The discovery of adenosine A2B receptors in the airways has raised great 
interest, and the presence of these receptors has now helped to explain some of 
adenosine physiological effects that had remained previously unexplained (Polosa  
et al., 2002; Holgate, 2005). Expression of these receptors was found in bronchial 
epithelium (Clancy et al., 1999), in cultured human airway smooth muscle 
(Mundell et al., 2001), in human mast cells (Marquardt et al., 1994), monocytes 
(Zhang et al., 2005) and fibroblasts (Zhong et al., 2005). Increasing evidence 
suggest that in rodents and man activation of adenosine A2B receptors modulates 
mast cell function; early studies on mast cells from mouse bone marrow showed 
that the ability of adenosine to cause mast cell degranulation was not affected by 
the selective adenosine A2A receptor agonist CGS 21680 (Marquardt et al., 1994). 
It was later shown that adenosine A2B receptors have a pro-inflammatory role, 
participating in the remodelling process occurring in chronic inflammatory lung 
diseases (Feoktistov et al., 2001; Zhong et al., 2004; Zhong et al., 2005), as 
confirmed by a study showing that activation of these receptors up-regulates 
several cytokines (IL-3, IL-4, IL-8 and IL-13) in mast cells and promotes IgE 
synthesis by lymphocytes B (Ryzhov et al., 2004a; Ryzhov et al., 2004b). This 
evidence suggests that adenosine A2B receptors are deeply involved in the 
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mechanisms underlying mediator release by mast cells and A2B antagonists with 
high selectivity hold a strong therapeutic potential. 
A3 adenosine receptors are the most recently discovered among adenosine 
receptors; both in vitro (Ramkumar et al., 1993; Thorne et al., 1996) and in vivo 
(Fozard et al., 1996; Shepherd et al., 1996) studies have established that activation 
of A3 receptors results in mast-cell degranulation and/or enhancement of 
degranulation in response to allergen in a variety of rodent species, but 
unfortunately the distribution of these receptors in rodents does not reflects 
distribution in humans; in fact, A3 receptor protein was not found in human mast 
cells, while it was found high density of this adenosine receptor in eosinophils 
both in the blood (Kohno et al., 1996; Knight et al., 1997) and in the airways 
(Walker et al., 1997), and activation of A3 receptors on human eosinophils 
mediates inhibition of degranulation and superoxide anion release (Ezeamuzie and 
Philips, 1999). Adenosine A3 receptors are also expressed in human neutrophils 
(Bouma et al., 1994) and their activation inhibits neutrophil degranulation induced 
by endotoxin (Gessi et al., 2002). Moreover, human lymphocytes express 
adenosine receptors with pharmacological and biochemical profile typical of the 
human A3 receptor subtype (Gessi et al., 2004). It was shown that mRNA and 
protein of adenosine A3 receptor are increased in lung from asthmatics (Walker et 
al., 1997). However, the functional role of these receptors in the asthmatic lung is 
unclear; in fact, it has been speculated that specific adenosine A3 receptor agonists 
might be useful in eosinophil-dependent allergic diseases such as asthma and 
rhinitis (Walker et al., 1997); conversely,  it has been more recently shown that A3 
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receptor signalling contributes to airways inflammation and lung eosinophilia in 
adenosine deaminase-deficient mice (Young et al., 2004).  
In conclusion, a detailed characterisation of adenosine receptor subtypes 
has been conducted in human and rodents lung tissues and isolated 
bronchoalveolar lavage cells to define their pharmacological role in adenosine-
induced responses in airways; however, the limited specificity of available 
adenosine receptor agonists and antagonists (Collins and Hourani, 1993; Olah and 
Stiles, 1995; Klotz et al., 1998) and conflicting studies results make difficult to 
define the adenosine receptor subtype responsible for adenosine-induced 
bronchoconstriction and inflammatory responses, but likely more than one 
receptor subtype is involved. 
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Figure 12: Adenosine receptors in the respiratory system. 
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4. ADENOSINE AND CARDIOPROTECTION 
 
In previous years, a protective effect on the injury caused by ischemia and 
reperfusion in the heart was attributed to adenosine, and these effects were 
documented in different experimental in vivo and in vitro models (Donato and 
Gelpi, 2003). Moreover, adenosine or adenosine receptor agonist administration 
prior to ischemia reduces the size of the infarction, improves the recovery of the 
ventricular function during reperfusion and prolongs the time period to the 
ischemic contracture (Donato and Gelpi, 2003). However, focusing on a potential 
therapeutic application it is important to understand the mechanisms involved in 
adenosine cardioprotection. 
 
4.1. Ischemic and reperfusion injury of the myocardium 
Acute myocardial infarction resulting from coronary artery occlusion is a 
common cause of morbidity and mortality worldwide; the therapeutic strategy is, 
therefore, to rapidly restore coronary flow using thrombolysis or percutaneous 
angioplasty to salvage as much ischemic myocardium as possible (Tissier et al., 
2008). 
Recent developments in immunology and cell biology have demonstrated 
the importance of inflammation in the pathogenesis of post-ischemic organ 
dysfunction. Whereas prolonged ischemia causes anoxic cell death, recent 
evidence suggests that sublethal injury may be amplified by inflammatory and 
cytotoxic injury cascades activated during the reperfusion period. Ischemia is a 
state of tissue oxygen deprivation accompanied by a reduced washout of the 
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resulting metabolites (Star, 1998); reperfusion is the restoration of blood flow to 
the ischemic tissue. Despite the unequivocal benefit of reperfusion of blood to an 
ischemic tissue, reperfusion itself can elicit a cascade of adverse reactions that 
paradoxically injure tissue (Bonventre, 1993); in fact, reperfusion injury has been 
well described in the literature to cause organ damage in the brain, heart, lungs, 
liver, kidneys and skeletal muscle. The susceptibility of tissue to ischemia 
reperfusion injury (IRI) is a major obstacle to both reperfusion after an infarct and 
successful organ transplantation. 
A growing body of evidence, primarily from animal models and 
preliminary human studies, has revealed that inflammatory mechanisms play a 
major role in the pathogenesis of ischemia/reperfusion injury, leading to the 
identification of multiple inflammatory mediators, including cytokines. The 
pathophysiology of the IRI is complex because the inflammatory aspect includes 
both cellular and humoral components, and mechanisms may be organ-dependent, 
with similar but distinct pathways involved in different organs. It was supposed 
that blood flow interruption to the tissue produces the accumulation of anaerobic 
metabolites and free radicals, but oxygen available with reperfusion generates 
reactive oxygen species (ROS) with oxidative cell damage, subsequent synthesis 
of cytokines and leukocyte-mediated tissue injury (Chamoun et al., 2000). 
 
4.2. Adenosine and cardiac ischemia/reperfusion injury 
Several biochemical substances released from the ischemic myocardium 
are capable of protecting the heart against ischemic insult (Parratt, 1993), and 
adenosine has cardioprotective effects in myocardial ischemia (Ely and Berne, 
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1992; Lasley and Mentzer, 1992; Thornton et al., 1992). It is known that 
adenosine concentration in the coronary effluent is markedly increased after 
ischemia (Kitakaze et al., 1993), and this nucleoside acts as an effector for 
myocardial cells, sympathetic nerve cells, endothelial cells, leukocytes and 
platelets, dysfunction of which may result in cellular injury (Hori and Kitakaze, 
1991). At the present, the exact source of extracellular adenosine in the injured 
tissue is not well defined, but likely results from a combination of intracellular 
metabolism and amplified extracellular phosphohydrolysis of adenine nucleotides 
via ecto-nucleotidases (Berne, 1980; Obata, 2002). There is evidence that 
myocardial ischemia also increases catecholamine levels (Dart et al., 1984; Rona, 
1985; Schomig, 1989; Strasser et al., 1992; Obata et al., 1994), and the 
stimulation of α1-adrenoreceptors by endogenous norepinephrine  with subsequent 
activation of protein kinase C (PKC) can increase adenosine production via 
activation of ecto-5’-nucleotidase; furthermore, increased nitric oxide (NO) 
facilitates the production of adenosine via cGMP-mediated activation of ecto - 5’-
nucleotidases (Obata, 2002). 
Adenosine has been implicated to protect against lethal reperfusion injury; in fact, 
it has been demonstrated that treatment with adenosine during reperfusion reduce 
infarct size in pre-clinical experiments and clinical trials (Gross and Auchampach, 
2007). Adenosine, has also been shown to be involved in the cardioprotection due 
to ischemic pre-condictioning (Lankford et al., 2006) . 
4.3. Adenosine receptors and cardioprotection 
All four adenosine receptors are expressed in different cell types of the 
heart and vessels, and thus the effects of adenosine and adenosine receptors on 
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myocardial responses to ischemia and reperfusion may not necessarily reflect 
direct myocyte responses but indirect actions at other cell types, including 
inflammatory cells; it was noted that A1 and A2A receptors are expressed in adult 
ventricular myocytes (Marala and Mustafa, 1998; Kilpatrick et al., 2002), while 
presently there is no definitive evidence that functional A3 or A2B proteins are 
expressed in adult mammalian myocytes. A1 receptor is the most extensively 
studied adenosine receptor subtype within the context of cardiac protection, but 
the A3 receptor was recently found to trigger protective responses similar to those 
for A1 receptor (though via distinct signaling); more recently, potential protective 
roles of A2A and A2B receptors attracted attention (Peart and Headrick, 2007). 
Protection with A1 receptor agonism was observed in all species examined, 
and recently a non-redundant role for endogenous A1 receptor activation in 
dictating intrinsic ischemic tolerance (the heart ability to withstand cellular injury 
and death during ischemic insult) was exposed through analysis of A1 receptor 
knockout mice (Reichelt et al., 2005; Morrison et al., 2006); it was shown that 
ischemia inhibits myocardial A1 receptor trascription in mice (Ashton et al., 
2003a; Ashton et al., 2003b), but further evidence is required. 
The two A2 subtypes (A2A and A2B receptors) are poorly understood in the 
context of myocardial ischemia/reperfusion, but are recently emerging as 
modulators of cardiovascular stress responses and, particularly, of inflammatory 
processes. In fact, both A2 subtypes possess important immunomodulatory 
functions and inflammation is important in both early and late aspects of injury 
and remodelling following ischemia/reperfusion; thus, these receptors can 
regulate the impact of inflammatory processes on ischemic and post-ischemic 
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damage. A2A-dependent cardioprotection includes inhibition of leukocyte-
dependent inflammatory processes (Visser et al., 2000; Sullivan et al., 2001), and 
possibly a direct inotropic action (Dobson and Fenton, 1997) which appears 
selective for post-ischemic tissue (Lasley et al., 2001); enhanced vasodilatation 
during reperfusion may also provide benefit with A2A agonism in experimental 
settings (Maddock et al., 2001; Peart et al., 2002), although with species 
differences (Peart and Headrick, 2007). 
Proposed protective or beneficial effects of the A2B receptor in 
ischemic/reperfused hearts could stem from responses mediated in other cell 
types; in fact, the A2B receptor is known to activate angiogenic factors (Feoktistov 
et al., 2002; Feoktistov et al., 2003) and trigger coronary endothelial growth 
(Dubey et al., 2002), while molecular targeting of this receptor impairs neo-
vascularization in non-cardiac tissues (Afzal et al., 2003); thus, the A2B receptor 
may play a key role in modulation of vascular growth and tissue remodelling. 
Acute genetic manipulation of this subtype expression in cardiac fibroblasts 
supported the hypothesis for a role as anti-proliferative and antifibrotic (Chen et 
al., 2004), congruent with effects of A2B receptor agonism in cardiac fibroblasts 
(Dubey et al., 2001). Thus, the adenosine A2B receptor may play a role in dictating 
the progression of post-ischemic changes in myocardial phenotype and post-
ischemic remodelling, limiting potential fibrosis and facilitating angiogenic 
growth (Wakeno et al., 2006). 
Throughout the 10 years since cloning and characterization of A3 receptor, 
this subtype has been shown to mediate cardioprotective effects in multiple 
species and models, but pronounced heterogeneity exists in the pharmacology of 
 60 
A3 agonists and antagonists across species (Muller, 2003), complicating 
interpretation and extrapolation of experimental findings; however, protection via 
this subtype appears to share some similarities with the A1 receptor but precisely 
where and how it mediates its protective actions remains unclear (Peart and 
Headrick, 2007). 
 
 
 
 
 
 
  
Figure 13: Adenosine receptors in the cardiovascular system. The two most important 
subtypes (cardiac A1 and vascular A2A receptors). 
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1. ADENOSINE AND ACUTE INFLAMMATION 
 
1.1. Materials and Methods 
1.1.1. Materials 
Aprotinin, bovine serum albumin (BSA), carrageenan, dimethyl sulfoxide 
(DMSO), o-dianisidine dihydrocloride, hexadecyltrimethylammonium bromide 
were purchased from Sigma (Italy). The adenosine A2A receptor agonist, 2-[p(2-
carboxyethyl)phenethylamino]-5’-N-ethylcarboxa-midoadenosine hydrocloride 
(CGS 21680), and the adenosine A2A receptor antagonist, 4-(2-[7-amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM 241385), 
were purchased from Tocris Bioscience (U.K.). Dithiothreitol (DTT), phenyl-
methylsulphonyl fluoride (PMSF) leupeptine were purchased from ICN 
Pharmaceuticals (Italy). Bradford reagent was purchased from Bio-Rad 
Laboratories (Italy). Polyclonal goat antibody to A2A receptor was purchased from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Anti-goat IgG conjugated to 
horseradish peroxidase was purchased from Dako (Denmark). ECL system was 
purchased from Amersham Pharmacia Biotech (Milan, Italy). All salts were 
purchased from Carlo Erba (Italy).  
 
1.1.2. Carrageenan oedema 
Male Wistar rats (120-150 g; Charles River, Italy) were slightly 
anaesthetized with enflurane and oedema was induced by injecting in the left hind 
paw carrageenan 1 % w/v (dissolved in distilled water; 0.1 ml); paw volume was 
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measured before carrageenan injection (time zero) and each hour for 6 hours, by a 
hydropletismometer (Ugo Basile, Comerio VA). Animals were divided in groups 
of 5 each and treated, just before oedema induction, with the selective adenosine 
A2A receptor agonist, CGS 21680 (0.02, 0.2 and 2 mg/kg intraperitoneally); with 
the selective adenosine A2A receptor antagonist, ZM 241385 (3 mg/kg ip.); with 
CGS 21680 (2 mg/kg ip.) plus ZM 241385 (3 mg/kg ip.) or with the vehicle 
(DMSO; 0.5 ml/kg ip.); an other group of rats was treated with CGS 21680 (30, 
100 and 300 µg/paw) or with the vehicle (DMSO; 0.1 ml/paw) injected locally 
with carrageenan. 
All animal experiments complied with the Italian D.L. n. 116 of 27 January 1992 
and associate guidelines in the European Community Council Directive of 24 
November 1986 (86/609/ECC). 
 
1.1.3. Western Blot analysis 
From different treated and control animals, at different times following 
oedema induction, inflamed paws were excised and the soft tissue was removed, 
frozen in liquid nitrogen and stored; the same tissue samples were also removed 
from non-inflamed animals. Tissue samples were then defrosted, weighed and 
homogenized with a Polytron homogenizer (3 cycles of 10 seconds at the 
maximum speed) in a lysis buffer containing: MgCl2, 2 mM; sodium 
ortovanadate, 100 µM; β-glycerophosphate, 50 mM; EGTA, 1 mM; DTT, 1 mM; 
PMSF, 1 mM; leupeptin, 10 µg/ml and aprotinin, 10 µg/ml. After centrifugation at 
2500 rpm for 10 minutes at 4°C, the supernatants were collected and centrifuged 
at 12000 rpm for 30 minutes at 4°C; the protein concentration was measured by 
the Bradford assay using BSA as standard. Membrane proteins (30 µg) were 
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briefly boiled and separated by 12 % sodium dodecyl sulphate (SDS)-
polyacrilamide gel electrophoresis (PAGE) and transferred onto nitrocellulose 
membranes for 45 min at 250 mA; non-specific antibody binding to the membrane 
was blocked with 5 % (w/v) non-fat milk and 0.1 % (w/v) BSA in PBS-Tween 20 
0.1 % for 2 hour at room temperature. Membranes were then incubated overnight 
at 4°C on a shaker with a polyclonal goat antibody to A2A receptor (1 : 500 in 
PBS-Tween 20 0.1 % containing 5 % non-fat milk and 0.1 % BSA); detection 
blots were washed with PBS-Tween 20 0.1% at 5 min intervals for 30 minutes 
and incubated with a secondary anti-goat antibody (1 : 5000) conjugated with 
horseradish peroxidase (HRP) for 2 hours at 4 °C. After 5 washes as described 
above, the immunoreactive bands were visualised using an enhanced 
chemiluminescence (ECL) system, as described by the manufacturer. 
 
1.1.4. Myeloperoxidase (MPO) activity assay 
Myeloperoxidase activity was measured as previously described (Mullane  
et al., 1985); from animals treated with the selective adenosine A2A receptor 
agonist, CGS 21680 (0.02, 0.2 and 2 mg/kg ip.) or with the vehicle (DMSO; 0.5 
ml/kg ip.), inflamed paws were excised after 3 hours from oedema induction and 
the soft tissue was removed, frozen in liquid nitrogen and stored. Tissue samples 
were then defrosted, weighed and homogenized in a solution containing 0.5 % 
(w/v) hexadecyltrimethylammonium bromide dissolved in 10 mM potassium 
phosphate buffer (pH 7) and centrifuged at 12000 rpm for 30 minutes at 4°C; an 
aliquot of the supernatant was then allowed to react with 0.167 mg/ml o-
dianisidine dihydrocloride and 0.001 % H2O2. The rate of change in absorbance 
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was measured spectrophotometrically at 650 nm; MPO activity was defined as the 
quantity of enzyme degrading 1 µmol/min of peroxide at 37°C and was expressed 
in milliunits per g of wet tissue (mU/g tissue). 
 
1.1.5. Statistical analysis 
All data are expressed as mean ± S.E.M. and analyzed by one way analysis 
of variance (ANOVA) followed by Dunnett’s test. A value of p < 0.05 was 
considered significant. 
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1.2. Results 
1.2.1. Effect of CGS 21680 on carrageenan oedema 
Injection of carrageenan in the rat hind paw caused an oedema peaking 
between 3 and 4 hours; intraperitoneal treatment with the selective adenosine A2A 
receptor agonist, CGS 21680, inhibited, in a dose-related manner (Figure 14), 
oedema development and this effect was reverted by co-administration with the 
selective adenosine A2A receptor antagonist, ZM 241385, while ZM 241385 alone 
did not modify oedema development (Figure 15). CGS 21680 administered 
locally with carrageenan also reduced oedema in a dose-related manner (Figure 
16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Effect of the selective adenosine A2A receptor agonist, CGS 21680 (0.02, 0.2 and 2 
mg/kg ip.), on carrageenan oedema; *p < 0.05, **p < 0.01 vs. vehicle. Dunnett’s test (n = 10). 
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Figure 15: Effect of the selective A2A receptor agonist, CGS 21680 (2 mg/kg ip.), of the 
selective A2A receptor antagonist, ZM 241385 (3 mg/kg ip.), and of CGS 21680 plus ZM 
241685 on carrageenan oedema; *p < 0.05, **p < 0.01 vs. vehicle; #p < 0.05,  ## p < 0.01 vs. 
CGS 21680 + ZM 241385. Dunnett’s test (n = 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Effect of the selective A2A receptor agonist, CGS 21680 (30, 100 and 300 µg/paw) 
administered locally, on carrageenan oedema; *p < 0.05, ***p < 0.001 vs. vehicle. Dunnett’s 
test (n = 10). 
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1.2.2. Western Blot of A2A receptor 
Western Blot analysis performed on paws excised at different times after 
oedema induction showed an increased A2A protein expression starting 1 hour 
following carrageenan injection, and peaking between the third and the fourth 
hour (Figure 17); the increased A2A protein expression observed at 3 hours after 
oedema induction was reduced to control values by treatment with CGS 21680 2 
mg/kg ip. (Figure 18). 
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Figure 17: Detection of adenosine A2A receptor and optical density analysis in inflamed 
paws; *p < 0.05, **p< 0.01 vs. control. Dunnett’s test (n = 3). 
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Figure 18: Effect of CGS 21680 (2 mg/kg ip.) on the proteic expression of the adenosine A2A 
receptor in inflamed paws (3 hours after carrageenan injection); *p < 0.05 vs. control; #p < 
0.05 vs. vehicle. Dunnett’s test (n = 3). 
 
1.2.3. MPO analysis 
MPO activity measured in inflamed paws excised 3 hours after 
carrageenan injection was reduced after treatment with CGS 21680, compared 
with control values, and  2 mg/kg ip. (Figure 19). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Effect of CGS 21680 (0.02, 0.2 and 2 mg/kg ip.) on myeloperoxidase (MPO) 
activity of inflamed paws (3 hours after carrageenan injection); **p < 0.01 vs. vehicle. 
Dunnett’s test (n = 3). 
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2. ADENOSINE AND BRONCHIAL HYPERREACTIVITY 
 
2.1. Materials and methods 
2.1.1. Materials 
Acetylcholine, adenosine, aluminium hydroxide gel, carbachol, 1,3-
dipropyl-8-cyclopentylxanthine (DPCPX), ovalbumin, pentobarbital, salbutamol 
and urethane were purchased from Sigma (Italy). Haematoxylin was purchased 
from J.T. Baker (Holland). Eosin was purchased from Kaltek (Italy). Avidin and 
biotin were purchased from Signet Inc. (Dedham, MA). 3,3’-diaminobenzidine 
(DAB), protein block serum free, anti-goat and anti-rabbit IgG biotinylated were 
purchased from Dako (Denmark). Polyclonal goat antibodies to A1, to A2A , A2B, 
A3 receptors and polyclonal rabbit antibody to β2-adrenergic receptor were 
purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). All salts and 
formalin were purchased from Carlo Erba (Italy). 
 
2.1.2. Sensitization and challenge with allergen 
Male Wistar rats (200-250g; Harlan, Italy) and male Brown Norway rats 
(200-250g; Charles River, Italy) were briefly anaesthetized with 4% isofluran in 
an anaesthetic chamber and were injected with ovalbumin mixed with aluminium 
hydroxide gel (50 mg/ml) 100 mg/kg ip. and 100 mg/kg sc. Starting from the 21st 
day after sensitization, rats were challenged with an aerosol of ovalbumin (5 
mg/ml; 2 ml per animal) or saline under sodium pentobarbital anaesthesia (60 
mg/kg ip); 24 hours thereafter, rats were used for the experiments. 
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All animal experiments complied with the Italian D.L. n. 116 of 27 January 1992 
and associate guidelines in the European Community Council Directive of 24 
November 1986 (86/609/ECC). 
 
2.1.3. Measurement of bronchoconstriction in vivo 
Animals were anaesthetized with urethane (10 ml/kg ip.; sol. 10 % w/v); 
the jugular vein and the carotid artery were cannulated respectively for drug 
administration and blood pressure monitoring. Rats were artificially ventilated (60 
breaths/min.; 1 ml/100 g tidal volume) via a tracheal cannula and connected to a 
bronchospasm transducer (Ugo Basile, Italy) to monitor change in airway 
resistance. All data were acquired by a coputerized system (McLab).  
After a stabilization period of 15 minutes, bronchoconstrictor responses to 
ovalbumin (1 mg/kg i.v.), adenosine (3 mg/kg i.v.) and carbachol (10 µg/kg i.v.) 
were established sequentially in groups of sensitized animals challenged with 
ovalbumin or saline and in control naïve rats. 
 
2.1.4. Drug treatment 
To investigate on the role of adenosine A1 receptor on airway 
hyperreactivity, different groups of sensitized ovalbumin challenged rats were 
pre-treated with the selective adenosine A1 receptor antagonist, 1,3-dipropyl-8-
cyclopentylxanthine (DPCPX; 100 µg/kg iv; - 5 minutes), before the 
administration of spasmogen agents. 
 72 
2.1.5. Bronchial tissue study in vitro 
Animals were sacrificed by cervical dislocation, exsanguinated and lungs were 
removed and placed into a Petri dish containing Krebs solution of the following 
composition (nM): NaCl, 115.3; KCl, 4.9; CaCl2, 1.46, MgSO4, 1.2; KH2PO4, 1.2; 
NaHCO3, 25.0 and glucose, 11.1; termosted at 37 °C and oxygenated (CO2 5% 
plus O2 95%); main bronchi were dissected free of parenchyma and mounted in 
2.5 ml isolated organ baths containing Krebs solution, at 37 °C, oxygenated (CO2 
5% plus O2 95%), and connected to an isometric force transducer (Ugo Basile, 
Italy) under a resting tension of 0.5 g. After about 60 minutes equilibration period, 
tissue reactivity was checked by evaluating the response to a single concentration 
of acetylcholine (Ach, 3 µM); after washing, a cumulative concentration response 
curve to salbutamol (0.001-0.4 µM) was performed on tissue pre-contracted with 
carbachol (1 µM). It was also evaluated the response to ovalbumin (10 µg) and to 
adenosine (300 µM) added before and after ovalbumin administration. All in vitro 
experiments were performed on tissues obtained from sensitized animals 
challenged with ovalbumin or with saline, and from control naïve rats. 
 
2.1.6. Western Blot analysis 
From different groups of sensitized and control animals, lungs were 
removed and homogenized as described above; protein samples (30 µg) were 
briefly boiled and subjects to electrophoresis on an SDS 10% polyacrylamide gel 
and transferred onto a nitrocellulose transfer membrane using standard procedure 
(described above). The membranes were placed in 5 % (w/v) non-fat milk and 0.1 
% (w/v) BSA in PBS-Tween 20 0.1 % for 1 hour at room temperature and then 
 73 
incubated with a polyclonal goat antibody to A1 receptor (1 : 500), to A2A receptor 
(1 : 500), to A2B receptor (1 : 250), to A3 receptor (1 : 250) or with a polyclonal 
rabbit antibody to β2-adrenergic receptor (1 : 500), all diluted in in PBS-Tween 20 
0.1 % containing 5 % non-fat milk and 0.1 % BSA, overnight at 4 °C. Detection 
blots were then washed with PBS-Tween 20 0.1% at 5 min intervals for 30 
minutes and incubated with a secondary anti-goat (1 : 5000) or anti-rabbit (1 : 
10000) antibody, both conjugated with horseradish peroxidase (HRP) for 2 hours 
at 4 °C. After 5 washes, the immunoreactive bands were visualised using an 
enhanced chemiluminescence (ECL) system, as described by the manufacturer. 
 
2.1.7. Histological analysis 
Lungs were fixed in 10% (v/v) buffered formalin via a tracheal cannula, 
then removed and immersed in formalin for 24 hours; sections were cut (8 µm 
thick) and stained with haematoxylin and eosin to demarcate cell types. The 
sections were analyzed by using a standard light microscope (original 
magnification: x 40) and photographed by a Leica DFC320 video camera (Leica, 
Italy) connected to the microscope using the Leica Application Suite software 
V2.4.0. Histological examination was performed on tissue samples from naive 
and sensitized challenged with ovalbumin or saline animals, to evaluate the effect 
of sensitization and ovalbumin challenge on lung morphology.  
 
2.1.8. Immunohistochemical analysis  
Main bronchi were removed, embedded in OCT (optimal cutting 
temperature) medium and frozen in liquid nitrogen; 8 µm cryostat sections were 
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prepared and fixed with acetone for 10 minutes, air dried and rehydrated with 
PBS. For staining, sections were incubated with 0.3 % H2O2 in methanol for 10 
minutes and protein block serum free was added for 30 minutes; endogenous 
biotin or avidin binding sites were blocked by sequential incubation for 15 min 
with avidin and biotin. Sections were then incubated with a polyclonal goat 
antibody to A1 receptor (1 : 300), to A2A receptor (1 : 75), to A2B receptor (1 : 75), 
to A3 receptor (1 : 75) or with a polyclonal rabbit antibody to β2-adrenergic 
receptor (1 : 300), all diluted in PBS containing 1 % BSA, for 1 hour; sections not 
incubated with primary antibody were used as negative control. Subsequently, 
sections were incubated with biotinylated anti-goat or anti-rabbit secondary 
antibody (both 1 : 500, for 15 minutes); enzymatic activity was detected with 3,3’-
diaminobenzidine (DAB) substrate (brown colour), while hematoxylin was used 
to counterstain (blue background). Sections were then dehydrated and mounted in 
Entellan® medium; images were taken by the Leica DFC320 video camera 
(Leica, Italy) connected to the microscope (original magnification: x 40) using the 
Leica Application Suite software V2.4.0. 
 
2.1.9. Statistical analysis 
All data are expressed as mean ± S.E.M. and analyzed by Student’s t-test 
for unpaired data, one way or two way analysis of variance (ANOVA) followed 
by Dunnett’s test, as appropriate. A value of p < 0.05 was considered significant. 
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2.2. Results 
2.2.1. Bronchoconstrictor responses to spasmogen agents in Wistar and 
Brown Norway rats  
In control naïve rats ovalbumin (1 mg/kg iv.) caused a bronchoconstriction 
of 16.65 ± 3.54 % (n=17), that was significantly augmented in Wistar sensitized 
rats challenged with ovalbumin (36.65 ± 5.47 %, n=17; p < 0.01), but not in 
Brown Norway sensitized rats challenged with ovalbumin (20.36 ± 4.29 %, n=11; 
p > 0.05) (Figure 20). Similarly, in control naïve rats adenosine (3 mg/kg iv.) 
caused a bronchoconstriction of 13.82 ± 3.09 % (n=17), that was significantly 
augmented in Wistar sensitized rats challenged with ovalbumin (30.06 ± 4.92 %, 
n=16; p < 0.01), but not in Brown Norway sensitized rats challenged with 
ovalbumin (16.70 ± 3.95 %, n=10; p > 0.05) (Figure 21). On the contrary, there 
was no significant difference in the bronchial response to carbachol (10 µg/kg iv.) 
among groups (Figure 22). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Bronchoconstrictor effect of ovalbumin (1 mg/kg iv.) in Wistar and Brown 
Norway rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with 
aerosol of OA; **p < 0.01 vs. control. Dunnett’s test (n = 11-17). 
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Figure 21: Bronchoconstrictor effect of adenosine (3 mg/kg iv.) in Wistar and Brown Norway 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA; **p < 0.01 vs. control. Dunnett’s test (n = 10-17). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Bronchoconstrictor effect of carbachol (10 µg/kg iv.) in Wistar and Brown 
Norway rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with 
aerosol of OA; p < 0.05 vs. control. Dunnett’s test (n = 10-16). 
 
 
2.2.2. Effect of allergen challenge on bronchial response to spasmogen agents  
Following these preliminary results, all successive experiments were 
performed on Wistar rats. In control naïve rats ovalbumin (1 mg/kg iv.) caused a 
bronchoconstriction of 16.65 ± 3.54 % (n=17), that was significantly augmented 
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in  rats sensitized and challenged with ovalbumin (36.65 ± 5.47 %, n=17; p < 
0.01), while no difference was observed between control rats and rats sensitized 
and challenged with saline (10.00 ± 1.52 %, n=10; p > 0.05) (Figure 23). 
Similarly, in control naïve rats adenosine (3 mg/kg iv.) caused a 
bronchoconstriction of 13.82 ± 3.09 % (n=17), that was significantly augmented 
in rats sensitized and challenged with ovalbumin (30.06 ± 4.92 %, n=16; p < 
0.01), while no difference was observed between control rats  and rats sensitized 
and challenged with saline (6.40 ± 2.38 %, n=10; p > 0.05) (Figure 24). On the 
contrary, there was no difference in the bronchial response to carbachol (10 µg/kg 
iv.) among groups. (Figure 25). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: Bronchoconstrictor effect of ovalbumin (1 mg/kg iv.) in Wistar rats actively 
sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of OA or 
saline (SA); **p < 0.01 vs. control. Dunnett’s test (n = 10-17). 
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Figure 24: Bronchoconstrictor effect of adenosine (3 mg/kg iv.) in Wistar rats actively 
sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of OA or 
saline (SA); **p < 0.01 vs. control. Dunnett’s test (n = 10-17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: Bronchoconstrictor effect of carbachol (10 µg/kg iv.) in Wistar rats actively 
sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of OA or 
saline (SA); p > 0.05 vs. control. Dunnett’s test (n = 10-16). 
 
 
2.2.3. Effects of A1 receptor blockade on bronchial response to spasmogen 
agents 
Pre-treatment with the A1 receptor antagonist DPCPX significantly 
reduced the bronchial response to ovalbumin and adenosine in sensitized rats 
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challenged with ovalbumin, compared to control animals pre-treated with the 
vehicle (ovalbumin, 22.20 ± 6.08 % vs. 54.17 ± 6.38 %, p < 0.01; adenosine 14.60 
± 3.29 % vs. 45.75 ± 5.23 %, p < 0.01. Student’s t-test, n=4-6) (Figure 26 and 27). 
No difference was observed in the bronchial response to carbachol (43.00 ± 10.24 
% vs. 63.33 ± 6.89 %, p > 0.05. Student’s t-test, n=5) (Figure 28).  
 
 
 
 
 
 
 
 
 
Figure 26: Effect of the adenosine A1 receptor antagonist, DPCPX (100 µg/kg given iv. 5 min. 
prior to ovalbumin), on response to ovalbumin (1 mg/kg iv.) in sensitized rats challenged 
with ovalbumin; **p < 0.01. Student’s t-test for unpaired data (n = 4-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Effect of the adenosine A1 receptor antagonist, DPCPX (100 µg/kg given iv. 5 min. 
prior to ovalbumin), on response to adenosine (3 mg/kg iv.) in sensitized rats challenged with 
ovalbumin; **p < 0.01. Student’s t-test for unpaired data (n = 4-6). 
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Figure 28: Effect of the adenosine A1 receptor antagonist, DPCPX (100 µg/kg given iv. 5 min. 
prior to ovalbumin), on response to carbachol (10 µg/kg iv.) in sensitized rats challenged 
with ovalbumin; p > 0.05. Student’s t-test for unpaired data (n = 4-6). 
 
 
2.2.4. Effect of ovalbumin and adenosine on bronchial tissue in vitro 
Adenosine (300 µM) administered before and after ovalbumin caused 
contraction of bronchial tissues obtained from sensitized rats challenged with 
ovalbumin or saline and from naïve rats, without any significant difference among 
animal groups.  Tissues from sensitized rats challenged with saline responded 
only weakly to ovalbumin (10 µg) (p > 0.05 vs zero; one sample Student’s t-test), 
while bronchi taken from sensitized animals challenged with allergen manifested 
a greater constrictor response to ovalbumin (p<0.05 vs zero; one sample Student’s 
t-test); no response to ovalbumin was observed in bronchi from naïve rats (Figure 
29). 
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Figure 29: Effect of ovalbumin (10 µg) and adenosine (300 µM given before and after 
ovalbumin) on bronchial tissues from rats actively sensitised to ovalbumin (OA) and 
challenged 24 hours previously with aerosol of OA or saline (SA); *p < 0.05 vs. zero. One 
sample Student’s t-test (n = 10-14).  
 
2.2.5. Salbutamol-induced bronchorelaxation in vitro 
Salbutamol caused a concentration-dependent relaxation of tissues from 
naïve rats and rats sensitized to ovalbumin with and without allergen challenge, 
but the sigmoidal concentration-response curve to salbutamol on bronchi from 
sensitized rats challenged with ovalbumin was lower than those obtained on 
bronchi from sensitized rats challenged with saline and from naïve rats, reflecting 
a reduction of the maximum relaxant effect of salbutamol following allergen 
challenge (Figure 30). 
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Figure 30: Effect of salbutamol (0.001-0.4 µM) on bronchial tissues pre-contracted with 
carbachol (1 µM) from rats actively sensitised to ovalbumin (OA) and challenged 24 hours 
previously with aerosol of OA or saline (SA); summary p < 0.001. Two way ANOVA (n = 10-
14). 
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2.2.6. Western Blot of adenosine receptors and β2-adrenergic receptor 
Pulmonary tissue of sensitized rats challenged with ovalbumin presented 
an increased proteic expression of adenosine A1 receptor, compared to the proteic 
expression of pulmonary tissue of sensitized rats challenged with saline and naïve 
rats (Figure 31). A2A receptor proteic expression was increased on pulmonary 
tissue from sensitized rats challenged with saline but not with allergen (Figure 
32); on the contrary, no difference was observed in the proteic expression of 
adenosine A2B and  A3 receptors, and of β2-adrenergic receptor (Figure 33, 34,35). 
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Figure 31: Detection of the adenosine A1 receptor and optical density analysis in lungs from 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA or saline (SA); *p < 0.05 vs. naive. Dunnett’s test (n = 3-4). 
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Figure 32: Detection of the adenosine A2A receptor and optical density analysis in lungs from 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA or saline (SA); **p < 0.01 vs. naive. Dunnett’s test (n = 3-4). 
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Figure 33: Detection of the adenosine A2B receptor and optical density analysis in lungs from 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA or saline (SA); p > 0.05 vs. naive. Dunnett’s test (n = 3-4). 
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Figure 34: Detection of the adenosine A3 receptor and optical density analysis in lungs from 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA or saline (SA); p > 0.05 vs. naive. Dunnett’s test (n = 3-4). 
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Figure 35: Detection of the β2-adrenergic receptor and optical density analysis in lungs from 
rats actively sensitised to ovalbumin (OA) and challenged 24 hours previously with aerosol of 
OA or saline (SA); p > 0.05 vs. naive. Dunnett’s test (n = 3-4). 
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2.2.7. Histological analysis 
In naïve rats lung sections were free of inflammation and edema (Figure  
36 A), and sensitized rats challenged with saline showed a similar profile (data not 
shown). In sensitized rats challenged with ovalbumin, peribronchial and 
perivascular edema and inflammatory cell infiltration were observed (Figure 36 B 
and C). 
 
 
Figure 36: Histological analysis of haematoxylin and eosin (H&E)-stained lung sections from 
naïve rats (A) and rats actively sensitised to ovalbumin (OA) and challenged 24 hours 
previously with aerosol of OA (B and C); original magnification: A and B x 100, C x 400. 
2.2.8. Immunoistochemical analysis 
Bronchial tissues from sensitized rats challenged with ovalbumin showed a 
strong positive immunoreactivity for adenosine A1 receptor compared to tissues 
obtained from sensitized rats challenged with saline and from naive animals; the 
enzyme was preferentially localized in the bronchial smooth muscle (Figure 37). 
On the contrary, bronchial tissue from sensitized rats challenged with saline and 
naïve rats showed a strong positive immunoreactivity in the smooth muscles for 
β2-adrenergic receptor, compared to tissues from sensitized rats challenged with 
ovalbumin (Figure 38). No positive immunoreactivity for adenosine A2A, A2B A3 
receptors was observed in bronchi from these groups of animals (Figure 39, 40, 
41). 
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Figure 37: Immunohistochemical localization of adenosine the A1 receptor in bronchi from 
naïve rats (B), sensitized rats challenged with saline (C) and sensitized rats challenged with 
ovalbumin (D). A is negative control; original magnification: x 40. 
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Figure 38: Immunohistochemical localization of adenosine the β2-adrenergic receptor in 
bronchi from naïve rats (B), sensitized rats challenged with saline (C) and sensitized rats 
challenged with ovalbumin (D). A is negative control; original magnification: x 40. 
A B 
C D 
 89 
 
Figure 39: Immunohistochemical localization of adenosine the A2A receptor in bronchi from 
naïve rats (B), sensitized rats challenged with saline (C) and sensitized rats challenged with 
ovalbumin (D). A is negative control; original magnification: x 40. 
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Figure 40: Immunohistochemical localization of adenosine the A2B receptor in bronchi from 
naïve rats (B), sensitized rats challenged with saline (C) and sensitized rats challenged with 
ovalbumin (D). A is negative control; original magnification: x 40. 
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Figure 41: Immunohistochemical localization of adenosine the A3 receptor in bronchi from 
naïve rats (B), sensitized rats challenged with saline (C) and sensitized rats challenged with 
ovalbumin (D). A is negative control; original magnification: x 40. 
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3. ADENOSINE AND MYOCARDIAL ISCHEMIA-
REPERFUSION INJURY 
 
3.1. Materials and methods 
3.1.1. Materials 
Ketamine and xylazine were purchased by Sigma (Italy). Polyclonal goat 
antibodies to A1 and A3 receptors were purchased from Santa Cruz Biotechnology 
Inc. (Santa Cruz, CA). Polyclonal mouse antibody to hypoxia inducible factor -1 α 
(HIF-1α) was purchased from Chemicon International Inc. (Temecula, CA). anti-
goat and anti-mouse IgG biotinylated were purchased from Dako (Denmark). All 
salts and formalin were purchased from Carlo Erba (Italy). 
 
3.1.2. Surgical preparation 
 Male Wistar rats (250-300g; Harlan, Italy) were anesthetized with 
ketamine 100 mg/kg ip. and xylazine 5 mg/kg ip.; rats were then placed in a 
supine position with their paws taped to the operating table. The trachea was 
cannulated and artificial respiration was maintained by a respirator with a 
frequency of 100 strokes/min and a tidal volume of 1 ml/100 g. A midline skin 
incision was made with reflection of the skin from the midsternal line; the chest 
was opened by a lateral cut along the left side of the sternum, cutting through the 
ribs to approximately the midsternum The animals were slightly rotated to the 
right to expose the left ventricle, and the auricle of the left atrium was slightly 
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retracted, exposing the entire left main coronary artery system; ligation was 
performed with a 6-0 silk suture (Ethicon®) passed with a tapered needle 
underneath the left anterior descending coronary artery (LAD), and a cotton 
tubing was placed on top of the vessel and a knot was tied on top of the cotton 
tubing to occlude the coronary artery. After occlusion for a period of  30 minutes, 
reperfusion was induced by cutting the knot on top of the cotton tubing; the chest 
cavity was closed and rats were allowed to recover. Twenty four hours later, rats 
were stunned by exposition to CO2, the chest cavity was re-opened and the heart 
was rapidly removed for in vitro study. 
All animal experiments complied with the Italian D.L. n. 116 of 27 January 1992 
and associate guidelines in the European Community Council Directive of 24 
November 1986 (86/609/ECC). 
 
3.1.3. Experimental protocol 
 Rats were randomly assigned to one of the three groups: sham-operated 
animals underwent identical surgical procedure but without ligation of the LAD; 
rats underwent ischemia (30 minutes) and immediate removal of the heart; rats 
underwent ischemia (30 minutes) and subsequent reperfusion (24 hours).  
 
3.1.4. Western Blot analysis 
From the three groups of animals, heart ischemic areas were removed, 
frozen in liquid nitrogen and stored; tissue samples were then defrosted, weighed 
and homogenized with a Polytron homogenizer (3 cycles of 30 seconds at the 
maximum speed) in a lysis buffer containing: NaCl, 150 mM; sodium 
 94 
ortovanadate, 100 µM; β-glycerophosphate, 50 mM; EDTA, 10 mM; DTT, 1 mM; 
PMSF, 1 mM; leupeptin, 10 µg/ml and aprotinin, 10 µg/ml. Centrifugations and 
protein concentration measurement were performed as described above; protein 
samples (100 µg) were briefly boiled and subjects to electrophoresis on an SDS 
10% polyacrylamide gel and transferred onto a nitrocellulose transfer membrane 
using standard procedure (described above). The membranes were placed in 5 % 
(w/v) non-fat milk and 0.1 % (w/v) BSA in PBS-Tween 20 0.1 % for 2 hours at 
room temperature and then incubated with a polyclonal goat antibody to A1 
receptor (1 : 500), to A3 receptor (1 : 250) or with a polyclonal mouse antibody to 
HIF-1α receptor (1 : 1000), all diluted in in PBS-Tween 20 0.1 % containing 5 % 
non-fat milk and 0.1 % BSA, overnight at 4 °C. Detection blots were then washed 
with PBS-Tween 20 0.1% at 5 min intervals for 30 minutes and incubated with a 
secondary anti-goat (1 : 5000) or anti-mouse (1 : 20000) antibody, both 
conjugated with horseradish peroxidase (HRP) for 2 hours at 4 °C. After 5 
washes, the immunoreactive bands were visualised using an enhanced 
chemiluminescence (ECL) system, as described by the manufacturer. 
 
3.1.5. Statistical analysis 
 All data are expressed as mean ± S.E.M. and analyzed by one way 
analysis of variance (ANOVA) followed by Dunnett’s test. A value of p < 0.05 
was considered significant. 
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3.2. Results 
3.2.1. Western Blot of HIF-1α and adenosine A1 and A3 receptors 
HIF-1α protein expression was weakly augmented (p < 0.05) in hearts 
underwent ischemia of 30 minutes, compared to tissues from sham rats, while 
expression of this protein was strongly increased (p < 0.01) in hearts underwent 
ischemia of 30 minutes and subsequent reperfusion of 24 hours (Figure 42). A1 
receptor protein expression was augmented in hearts underwent ischemia of 30 
minutes, compared to tissues from sham rats, while expression of this protein was 
not modified in hearts underwent ischemia of 30 minutes and subsequent 
reperfusion of 24 hours (Figure 43); A3 receptor protein expression was reduced 
in hearts underwent ischemia alone and in hearts underwent ischemia plus 
reperfusion, compared to tissues from sham-operated rats (Figure 44). 
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Figure 42: Detection of HIF-1α and optical density analysis in ischemic and 
ischemic/reperfused hearts; *p < 0.05, **p< 0.01 vs. control. Dunnett’s test (n = 3). 
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Figure 43: Detection of adenosine A1 receptor and optical density analysis in ischemic and 
ischemic/reperfused hearts. 
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Figure 44: Detection of adenosine A3 receptor and optical density analysis in ischemic and 
ischemic/reperfused hearts. 
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4. DISCUSSION 
 
4.1. Adenosine A2A receptor and acute inflammation 
The adenosine A2A receptor is expressed on several inflammatory cells and 
its activation results in the inhibition of these cell function (Linden, 2006); thus, 
recently much attention has been focused on the possible antinflammatory effect 
of adenosine A2A receptor agonists (Lappas et al., 2005).  
In order to investigate on the role of adenosine A2A receptor in acute 
inflammation, we evaluated the effect the synthetic A2A receptor selective agonist, 
CGS 21680, on  carrageenan-induced rat paw oedema, a classical model of acute 
inflammation widely used to test the potential antinflammatory of new molecules. 
Our results show that CGS 21680, administered intraperitoneally immediately 
before oedema induction, reduces, in a dose-dependent manner, local acute 
inflammation induced by carrageenan injection in the rat paw; at the highest dose 
(2 mg/kg) used, CGS 21680 completely blocks oedema development. To assess 
the specificity of the response to CGS 21680, we also treated rats with the 
synthetic A2A receptor selective antagonist, ZM 241385, in combination with CGS 
21680. We  observed that the inhibitory effect of CGS 21680 on carrageenan 
oedema was reverted by the concomitant administration of ZM 241385, 
confirming that CGS 21680 effect is mediated through systemic A2A receptor 
activation; on the contrary, ZM 241385 alone did not modify the extent of 
inflammation. 
Moreover, as marker of neutrophil accumulation (Mullane et al., 1985), we 
measured myeloperoxidase activity in the inflamed paws; we found that the 
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intraperitoneal treatment with CGS 21680 inhibited, in a dose-dependent manner, 
the increase in MPO activity in the inflamed tissue; the effect of the highest dose 
(2 mg/kg) of CGS 21680 was highly significant. This finding suggests that A2A 
receptor activation mediated by CGS 21680 might inhibit acute local 
inflammation, at least in part, by inhibiting neutrophil sequestration and function; 
this result is in accordance with evidence that neutrophils express adenosine A2A 
receptors on their membrane surface and with the previous findings showing that 
the antinflammatory effects of A2A agonists are due to inhibition of neutrophil 
sequestration (Ross et al., 1999; Sullivan et al., 2004; Odashima et al., 2005; 
Linden et al., 2006).      
The expression and the function of adenosine receptors are regulated by 
endogenous factors involved in the inflammatory response, such as growth factors 
(Arsalan et al., 1997; Navarro et al., 1999), glucocorticoids (Svenningsson and 
Fredholm, 1997; Ren and Stiles, 1999) and cytokines (Khoa et al., 2001; 
Trincavelli et al., 2002). In particular, inflammatory cytokines up-regulate the 
function and expression of A2A receptors in human monocytic THP-1 cells (Khoa 
et al., 2001) and in rat PC12 cells (Trincavelli et al., 2002), while nerve growth 
factor down-regulates A2A receptor expression in PC12 cells (Malek et al., 1999). 
In our work,  Western Blot analysis of inflamed paws shows that there is a time-
dependent increase in A2A receptor proteic expression in the inflamed tissue, with 
an early increase starting 1 hour following the oedema induction, peaking between 
the third and the fourth hour and declining at 5 hours; this result suggests that A2A 
adenosine receptor upregulation in the inflamed tissue might represent  receptor 
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functionality and might be involved in the regulation of downstream regulatory 
proteins.  
Following systemic treatment with CGS 21680, concomitant to edema and 
MPO activity inhibition in the paw,  we observed that A2A proteic expression was 
down-regulated compared to the receptor expression measured in inflamed paws 
from non-treated animals.  These findings strongly suggest that A2A adenosine 
receptor expression in vivo, likely regulated by endogenous factors  involved in 
inflammation, might be part of a homeostatic mechanism able to limit tissue 
damage following inflammation. In this respect, it has been demonstrated that in 
mice lacking A2A receptor there is an exacerbation of inflammation compared to 
wild type mice  (Ohta and Sitkovsky, 2001).  
We have also evaluated the effect of CGS 21680 when administered 
locally, to better investigate on the antinflammatory effect of this drug; 
interestingly, CGS 21680 is active either when given locally and when given 
systemically, indicating that this drug might negatively modulate an inflammatory 
reaction through the A2A receptor activation at the site of inflammation, even if 
other mechanisms forward from the lesion are probably involved, for example the 
systemic release of mediator(s).  
Taken together, our results confirm the importance of adenosine A2A 
receptor in the modulation of inflammation and suggest that  agonists at this 
receptor may act as antinflammatory drugs with possible high clinical potential. 
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4.2. Adenosine receptors and airway hyperreactivity 
 The heightened sensitivity of asthmatics to a range of stimuli 
(immunological, physical and pharmacological) that ordinarily are without effect 
in normal subjects is a defining characteristic of asthma (Woolcock 1997); this 
phenomenon is termed bronchial, or airway, hyperreactivity, and results in 
facilitation of bronchospasm that contributes to the airway obstruction 
characteristic of asthma (Cockcroft , 1997). The phenomenon is particularly well 
exemplified by the broncocostrictor response to adenosine which is prominent in 
asthmatic patients and generally not present in control subjects (Cushley et al., 
1983); indeed, bronchoconstriction to adenosine was demonstrated in a number of 
animal models, but with contrasting results. 
Several rat strains have been used in experimental animal models to mimic 
airway hyperresponsiveness seen in asthmatics; in this study we performed 
preliminary experiments in two rat strains, Brown Norway and Wistar, in order to 
compare bronchial reactivity following sensitization. Although several authors 
develop the allergic asthma model in the Brown Norway rat strain, since this 
strain is known to have a highly susceptive immune system  (Hannon et al., 2001; 
Tigani et al., 2003), in our experimental study we were able to induce airway 
hyperreactivity in Wistar rats but not in Brown Norway rats.  Indeed, our results 
in vivo show that only Wistar rats actively sensitized and aerosolized with 
ovalbumin (according to our experimental protocol of sensitization and allergen 
challenge) show an increased bronchial response to both ovalbumin (allergen) and 
adenosine compared to control naïve rats; this bronchial hyperreactivity cannot be 
elicited by sensitization and further allergen challenge in Brown Norway rats (as 
 101 
summarized in Figure 45). Our results are in agreement with those obtained 
previously by other authors showing that Wistar appears to be the best rat strain to 
induce airway hyperreactivity (Chiba and Misawa, 1993). Thus, we performed all 
the following experiments on Wistar rats.  
Our findings demonstrate that sensitization and subsequent challenge with 
ovalbumin elicits, only in Wistar rats, bronchial hyperreactivity that is proven by 
an increased bronchoconstriction in response to both adenosine and allergen. On 
the contrary, we didn’t find any significant difference in the response to carbachol 
(10 µg/kg) among animal groups; we used carbachol administration as a control of 
bronchial reactivity at the end of each single in vivo experiment. In addition, 
histological analysis showed evidence of peribronchial and perivascular 
inflammation with cell infiltration in the lung only from rats sensitized and 
aerosolized; this finding shows that ovalbumin challenge is essential also to 
induce features of pulmonary inflammation.  
 
 
 
 
 
 
 
 
 
 
 
Figure 45: Bronchoconstrictor effect of ovalbumin (1 mg/kg iv.), adenosine (3 mg/kg iv.) and 
carbachol (10 µg/kg iv.) in Wistar and Brown Norway rats actively sensitised to ovalbumin 
(OA) and challenged 24 hours previously with aerosol of OA; **p < 0.01 vs. control. 
Dunnett’s test (n = 10-17). 
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There is evidence that exposition to allergen subsequent to sensitization is 
crucial to induce bronchial hyperreactivity and that bronchoconstriction in 
response to adenosine is a marker of airway hyperreactivity, both in experimental 
animals and in humans (Hannon et al., 2001); however, the mechanism at the 
basis of adenosine-induced bronchoconstriction is still unknown. We evaluated 
the bronchial response to spasmogen agents in rats sensitized with and without 
ovalbumin challenge to assess a possible difference among animal groups; we 
observed that sensitization per se does not increase the sensitivity of the airways 
to ovalbumin and adenosine while allergen exposure appears to be crucial. This 
finding is in accordance with clinical observations about asthma; in fact, 
asthmatics undergo regular exposure to allergen, a situation which would 
resemble more that of sensitised aerosolised animals than that of animals 
sensitised but not exposed to allergen.  
The mechanism at the basis of bronchial hyperreactivity and adenosine-
induced bronchoconstriction in humans and sensitized animals has not yet been 
elucidated, nor it has been established which adenosine receptor is involved, but 
there is evidence that the receptor responsible varies among animal species. 
Indeed, it has been suggested that adenosine-induced bronchoconstriction is 
mediated by A1 and A2B receptors in rat and mouse; A3 receptor in rat, guinea pigs 
and mouse; A2B receptor in humans (Spicuzza et al., 2006); however, more 
investigations are needed to clarify this scenario. It has been supposed that 
adenosine and A1 receptor are central players in the development of airway 
hypersensitivity and the inflammatory response to allergen (Richardson, 1997). It 
was reported that two interesting changes that occur in the human lung with the 
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onset of asthma are an increase in the mucosal concentration of adenosine and the 
“appearance” of the A1 receptor role (Richardson, 1997). It was also reported that 
it is very difficult to detect this receptor in normal lung tissue (Dixon, 1996), but 
in asthmatic lungs its presence is associated with the ability of adenosine to 
induce bronchoconstriction (not seen in normal lungs).  
By Western Blot analysis, we observed that proteic expression of 
adenosine A1 receptor on the lung of rats sensitised and aerosolised with 
ovalbumin was increased compared to the receptor expression on lung of 
sensitized rats but not challenged with allergen; immunohistochemical analysis 
shows that the receptor is localized on bronchial smooth muscles. This finding is 
in agreement with an other work that showed an increased expression of A1 
receptor in small airways from allergic rabbits compared with that in small 
airways from normal rabbits (Ali et al., 1994); moreover, asthmatic patients are 
believed to have increased expression of A1 receptors in the lung (Tilley and 
Boucher, 2005). Here, we demonstrate that in sensitized rats challenged with 
allergen the increased airway hyperrectivity is associated to an increased A1 
receptor expression localized on bronchial smooth muscles. To evaluate whether 
bronchial A1 receptor  was responsible for airway hyperreactivity observed in 
sensitized allergen challenged rats, we performed also experiments in groups of 
rats pre-treated with the synthetic A1 receptor selective antagonist, DPCPX. 
Interestingly, our data show that DPCPX reduces not only adenosine-
induced bronchoconstriction in sensitized rats aerosolized with allergen, but also 
allergen-induced bronchoconstriction, in the same group of rats.  This result 
strongly suggests that adenosine A1 receptor contributes to airway hyperreactivity 
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caused by exposure to allergen of sensitized rats. Our findings are in agreement 
with emerging experimental data providing evidence for A1 receptor as an 
important target in bronchial asthma (Obiefuna et al., 2005). Moreover, positive 
results in human asthmatics have been obtained from clinical trials with an 
antisense oligonucleotide to adenosine A1 receptor (Ball et al., 2003). 
Furthermore, recently it has been shown an increased expression of A1 receptor on 
bronchial epithelium and airway smooth muscle of asthmatic subjects (Brown et 
al., 2007).  
It is now also important to understand how and where adenosine A1 
receptor exerts its effects in the human lung; there is already evidence that 
adenosine can activate mast cells, and this has been considered the main 
mechanism of bronchospasm in asthmatics (Holgate et al., 1987). But in normal 
lungs, A3 receptors mediate the adenosine-dependent activation of mast cells, 
while it is not clear if A1 receptors mediate mast cell activation in asthmatic lungs; 
moreover, it has been shown that A1 receptor elicits bronchospasm even in 
absence of mast cell activation (Meade et al., 1996). In sensitized guinea pigs, it 
has been recently suggested that adenosine-induced bronchoconstriction is 
dependent on a neuronal mechanism through A1 receptor activation (Keir et al., 
2006). Thus, to date it is known that adenosine A1 receptor mediated 
bronchoconstriction may involve effects on neural pathways, smooth muscle and 
inflammatory cells.  Taken together, our in vivo results confirm a provocative role 
for the adenosine A1 receptor in airways, while its block could be beneficial in 
asthma therapy. 
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Western Blot analysis also showed increased expression of the A2A 
receptor in lungs from sensitised rats, returning to control levels after allergen 
challenge. However, this increased A2A proteic expression was not paralleled by 
receptor immunoreactivity on bronchial tissue. Thus, we guess that the increased 
A2A proteic expression in lung homogenates from sensitized non-allergen 
challenged rats could reflect receptor expression on cells present in the pulmonary 
tissue. It was recently shown (Morello et al., 2006) that inflammatory stimuli, 
such as IL-1β and TNF-a, increase the expression of the A2A gene and protein 
levels in lung epithelial cells in vitro. Our experiments, described above, on 
carrageenan-induced rat paw edema demonstrate that acute inflammation is 
associated to an increased A2A receptor expression that likely plays a protective 
role able to limit tissue damage. One could speculate that in sensitized rats not 
exposed to allergen the increased A2A receptor pulmonary expression is involved 
in the protection from airway hyperreactivity. Such an effect of A2A would be loss 
following allergen challenge and A1 receptor up-regulation. However, this point 
needs to be further investigated.  
 It has also been shown an increased A2B receptor expression in peripheral 
blood mononuclear cells from asthmatic patients (Zhou et al., 2001) and, more 
recently, in  airways and lungs of smokers with COPD (Varani et al., 2006).  In 
addition, up-regulation of adenosine A3 receptor is thought to occur in sensitized 
guinea pigs and humans with inflammatory airway disorders (Mundell et al., 
2001; Walker et al., 1997).  However we observed no difference in the proteic 
expression of the adenosine A2B and A3 receptors on lungs from the three groups 
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of animals studied, and no immunoreactivity was observed of these receptors in 
bronchi from the three animal groups. 
We also performed in vitro experiments, on isolated bronchi from rats 
sensisitized and challenged with aerosolized ovalbumin  ex vivo.  The  significant 
augmentation of the bronchoconstrictor response to allergen was reproduced in 
isolated bronchi obtained from ex vivo sensitized rats challenged with ovalbumin; 
conversely, there was no difference in response to adenosine on isolated bronchi 
obtained from the three different animal groups. Thus, the bronchial 
hyperreactivity conferred by allergen challenge, and evaluated as an increased 
response to adenosine, is lost on isolated bronchi. This finding would suggest that 
in vivo the increased bronchoconstriction in response to adenosine is likely 
dependent upon an indirect mechanism probably activated following A1 
stimulation. We do not know what mechanism and which mediators are involved, 
neither whether this indirect mechanism is wholly or only partly responsible for 
the response to adenosine. However, evidence that in vivo treatment with DPCPX, 
the selective A1 antagonist, only inhibits but not abolishes the increased response 
to adenosine supports the hypothesis of an adjunctive mechanism apart from A1 
involvement.   
There is evidence that asthmatic subjects present a reduced bronchial 
response to β2-agonsits, whose cause is still a matter of debate. The “β-adrenergic 
theory”, as proposed by Szentivanyi in 1968, tried to explain with β-adrenergic 
dysfunction the cause of bronchial hyperreactivity and of all atopic diseases. It 
was found that asymptomatic asthmatic patients presented a number of β-
receptors similar to that of a normal control group, while symptomatic asthmatic 
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patients presented a significantly decreased receptor number when compared to 
both groups, suggesting that this difference could be cause of the disease 
(Gamboa et al., 1991); however, in another study, it was found a significant 
decrease of β-receptor numbers after bronchial allergic provocation test in 
asymptomatic asthmatic patients, thus suggesting that the reduced β-adrenoceptor 
number would likely be the consequence and not the cause of atopic disease 
(Gamboa et al., 1990). Furthermore, the reduced response of asthmatics to β2-
agonists has also been attributed to receptor desensitization due to a prolonged 
exposure to the agonists, or to genetic polymorphisms leading to variants of β2-
recptors with different functional properties (Broadley, 2006).  
We assessed the response to salbutamol of isolated bronchi from ex vivo 
sensitized rats, to evaluate possible differences among animal groups under 
investigation. Our data show that salbutamol-induced relaxation on isolated 
bronchi from rats sensitised and aerosolised with ovalbumin was reduced in 
comparison to the response obtained on bronchi isolated from naïve and from 
sensitized rats not exposed to allergen. In parallel, immunohistochemical analysis 
showed a reduced immunoreactivity for β2-adrenoceptor on bronchial smooth 
muscle from group of rats exposed to allergen, compared to the other groups, that 
could be likely caused by receptor desensitization with a mechanism of 
internalization, sequestration or receptor breakdown, leading to the loss of 
receptors from cell surface (Johnson et al., 1998). Our results suggest that the 
reduced β2-adrenoceptor number on airway smooth muscle would account for the 
reduced response to salbutamol and would  be consequent to allergen exposure.  
Thus, our findings further support the hypothesis of early clinical studies 
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suggesting that decrease of β2-receptors could be the consequence of atopic 
diseases and secondary to the immunological events that follow antigen-antibody 
reactions and cell membrane changes (Gamboa et al., 1990; Gamboa et al., 1991; 
Oehling et al., 1991). There is evidence that bronchial hyperreactivity following 
allergen exposure could be linked to the reduced β2-receptor number or sensitivity  
(Nielson et al., 1992); but the mechanism at the basis of β-adrenergic 
desensitization has not yet been clarified; however, several inflammatory 
mediators likely present in asthmatic airways have been shown to be involved 
(Shore and Moore, 2002; Hirst et al., 2003; Rovati et al., 2006).  
In conclusion, our study suggests that allergen exposure of sensitized rats 
causes airway hyperresponsivenes to ovalbumin that might be related to a reduced 
number of β2-adrenoceptor, likely dependent upon receptor desensitization 
evaluated as a reduced response to salbutamol. Conversely, hyperresponsiveness 
to adenosine, also caused by allergen exposure, cannot be explained by β2-
adrenoceptor desensitiziation since, under our experimental conditions, it is lost 
on isolated tissues; thus, in agreement with other authors (Broadley, 2006; Keir et 
al., 2006), we hypotesise that it is mostly due to an indirect mechanism probably 
involving sensory nerves and/or inflammatory cell activation.    
 
4.3. Adenosine receptors and myocardial ischemia/reperfusion 
injury  
The microenviroment of injured and inflamed tissues is characterized by 
low levels of oxygen and inflammation/injury-related hypoxia can be expected to 
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activate hypoxia-inducible factor 1 (HIF-1), an ubiquitous transcription factor, 
which functions as a master regulator of oxygen homeostasis (Semenza, 2001; 
Berra et al., 2006; Fandrey et al., 2006). Active HIF-1 is a heterodimer consisting 
of an inducible HIF-1α subunit and a constitutively expressed HIF-1β subunit and 
regulating the expression, under pathological conditions, of numerous genes 
which encode proteins that are prosurvival in nature and can result in 
cytoprotection (Lefer, 2006). In fact previous studies demonstrated that stable 
expression or activation of HIF-1α can protect isolated cardiac myocytes and 
isolated hearts against ischemia/reperfusion injury (Date et al., 2005; Ockaili et 
al., 2005). In addition, it was found that HIF-1α could be considered a sensitive 
auxiliary diagnostic marker of hypoxia; in fact, its expression, as yet discussed, is 
very low in non-hypoxic tissues, including cardiac muscle, while its gene 
expression is up-regulated within several minutes after ischemia, including 
myocardial ischemia and remains high if the inducement continues (Li et al., 
2007). We measured HIF-1α levels in rat cardiac tissue samples, expecting a 
modulation of this protein among animal groups; we found an augmented protein 
expression of HIF-1α in ischemic hearts (p < 0.05), and a strongly augmented 
expression of this factor in ischemic/reperfused hearts (p < 0.01), compared to 
non-ischemic hearts. This finding is in accordance also to an other recent work 
(Cai et al., 2007) which show that HIF-1 α is required for myocardial protection 
against ischemia/reperfusion injury. 
It is now well established that adenosine functions as a potent intrinsic 
cardioprotective molecule; in particular, the binding of adenosine to A1 receptor is 
the initial step in triggering this protective mechanism against myocardial 
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infarction (Yang et al., 2002). It was demonstrated that the effects of adenosine 
are limited by receptor number rather than by agonist concentration in ischemic 
murine myocardium (Matherne et al., 1997); in addition, it was shown, using 
transgenic techniques, that cardiac adenosine A1 receptor over-expression 
activates endogenous protective mechanisms that provide the heart with increased 
resistance to ischemia/reperfusion injury (Yang et al., 2002). Furthermore, it has 
been shown that adenosine may regulate HIF-1 expression in cells under hypoxic 
and normoxic conditions (De Ponti et al., 2007; Kong et al., 2006). We measured 
proteic expression of the adenosine A1 receptor to evaluate a possible change of 
its levels after myocardial ischemia and reperfusion; we found an augmented 
expression of A1 receptor in ischemic hearts, returning to basal levels following 
reperfusion; this finding suggests that ischemia injury itself causes an over-
expression of this receptor, that might operate as immediate cardioprotective 
mechanism after myocardial damage. 
On the other hand, the functional importance of the adenosine A3 receptor 
in modulating injury during myocardial ischemia remains to be determined; it was 
supposed that this receptor is involved in adenosine cardioprotection (Kilpatrick et 
al., 2001), but it was also shown that mice lacking functional A3 receptor are more 
resistant to the development of irreversible ischemic injury, suggesting an 
injurious role for this receptor during myocardial ischemia, probably potentiating 
the inflammatory response (Guo et al., 2001). We measured proteic expression of 
the adenosine A3 receptor to evaluate a possible change of its levels too, after 
myocardial ischemia and reperfusion; our results showed a reduction of A3 protein 
expression after ischemia and also after 24 h reperfusion, suggesting that 
 111 
ischemia/reperfusion injury itself causes a down-regulation of this receptor, with a 
restriction of its possible harmful action.  
Taken together, our preliminary results suggest that adenosine A1 and A3 
receptors might have opposite effects in modulating injury during myocardial 
ischemia; thus, as yet supposed (Yang et al., 2002), strategies designed to 
moderately modify the density of adenosine receptors in the myocardium might 
have clinical potential. 
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5. CONCLUSIONS 
 In this study, we have investigated on the role of adenosine and 
adenosine receptors in three different rat models involving the inflammatory-
immune system: paw oedema (acute inflammation), airway hyperresponsiveness 
(immunological inflammation) and myocardial ischemia/reperfusion injury. 
Indeed, bronchial asthma and ischemia-reperfusion injury after myocardial 
infarction are disorders characterized by an underlying inflammatory process. Our 
results confirm a pivotal role of adenosine in inflammation and are further 
evidence for adenosine receptors as therapeutic targets of inflammatory disorders. 
 To date there is growing evidence that adenosine receptors could be 
promising therapeutic targets in a wide range of pathologies, including 
cardiovascular diseases (cardiac arrhythmia and ischemia), nervous system 
disorders (dementia, Parkinson’s disease and other neurodegenerative diseases; 
hyperactivity, anxiety, schizophrenia and sleep disorders) renal system diseases, 
pulmonary disorders (bronchial asthma and chronic obstructive pulmonary 
disease), immune and inflammatory disorders, endocrine disorders (diabetes) and 
cancer.  
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Figure 46: Novel disease targets for selective adenosine receptor ligands. 
  
 After more than three decades of pharmaceutical research, several 
therapeutic targets related to the “adenosinergic system” have been specified, 
while a considerable number of selective agonists and antagonists of adenosine 
receptors have been discovered, and some have been clinically evaluated; 
however, none among adenosine receptor modulators has yet received regulatory 
approval.  
 Indeed, it is surprising to note that only the same adenosine is to date in 
clinical use. In fact, Adenoscan® (adenosine 30 mg/10 ml, for iv. use) is indicated 
as an adjunct to thallium201 myocardial perfusion scintigraphy for coronary 
vasodilation in patients unable to exercise adequately; Krenosin® (or 
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Adenocard®; 6 mg/2 ml, for iv. use) is indicated in cardiac arrhythmia 
(conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), 
including that associated with accessory bypass tracts (Wolff-Parkinson-White 
Syndrome). On the other hand, adenosine receptors are major targets of caffeine 
and other xanthines (theophylline and theobromine), the most “commonly 
consumed drugs” in the world.  
 One reason for this enigma is the ubiquity of adenosine receptors and 
the possibility of side effects; in addition, species differences in the affinity of 
putatively selective ligands complicated pre-clinical testing in animal models. 
Local administration, with selective activation and blockade of these receptors, 
could be a good strategy to overcome these obstacles; an other recent strategy is 
that of “neoceptors”: reengineered adenosine receptors that can recognize 
uniquely modified nucleosides that are inactive at the native adenosine receptors. 
This neoceptor strategy is intended for eventual use in organ-targeted gene 
therapy and has yet led to development of neoceptors for adenosine A2A and A3 
receptors (Jacobson and Gao, 2006).  
In conclusion, recent advances in the understanding of the roles of the 
various adenosine receptor subtypes and in the development of selective and 
potent ligands, together with new findings in pathogenetic mechanisms of various 
diseases can make possible therapeutic applications of  drugs interfering in the 
“adenosine system”. 
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